



(86) Date de dépôt PCT/PCT Filing Date: 2006/02/23
(87) Date publication PCT/PCT Publication Date: 2006/08/31
(85) Entrée phase nationale/National Entry: 2008/01/03
(86) N° demande PCT/PCT Application No.: US 2006/006730
(87) N° publication PCT/PCT Publication No.: 2006/091885
(30) Priorité/Priority: 2005/02/24 (US60/656,232)

(51) Cl.Int./Int.Cl. *C07D 323/00* (2006.01),
A61K 31/519 (2006.01), *C07D 475/06* (2006.01)
(71) Demandeur/Applicant:
DR PHARMA NOVA, LLC, US
(72) Inventeurs/Inventors:
REIS, ALAN J., US;
SCHAFMEISTER, CHRISTIAN, US
(74) Agent: CASSAN MACLEAN

(54) Titre : PROCEDE D'ENREGISTREMENT ET SYSTEME DE CONTROLE POUR MEDICAMENTS DES LISTES II-V
DE LA DRUG ENFORCEMENT AGENCY (DEA)
(54) Title: A REGISTRY METHOD AND CONTROL SYSTEM FOR DEA SCHEDULE II-V MEDICINES

(57) **Abrégé/Abstract:**

The present invention provides compositions and methods for synthesizing labeled drugs. The present invention further provides methods for preventing or stopping prescription drug abuse for all agents registered as a Drug Enforcement Agency (DEA) schedule II through schedule V medications. According to the present invention, methods are provided for monitoring patient compliance with prescribed drug treatment. The present invention also provides methods for facilitating a replacement prescription when a patient is left without access to their prescribed drug. Furthermore, the present invention provides a method to improve employee compliance with an employer's drug policies via either a voluntary or compulsory system for enhanced drug testing.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/091885 A3

(51) International Patent Classification:

C07D 323/00 (2006.01) *C07D 475/06* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2006/006730

(22) International Filing Date:

23 February 2006 (23.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/656,232 24 February 2005 (24.02.2005) US

(71) Applicant (*for all designated States except US*): **DR PHARMA NOVA, LLC** [US/US]; One Northgate Square, Greenburg, PA 15601 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **REIS, Alan, J.** [US/US]; 5107 Ellsworth Ave., Pittsburgh, PA 15232 (US). **SCHAFMEISTER, Christian** [US/US]; 4916 Wallingford St., Pittsburgh, PA 15213 (US).

(74) Agents: **LUDWIG, Peter, S.** et al.; Darby & Darby P.C., P.O. Box 5257, New York, NY 10150-5257 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
28 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A REGISTRY METHOD AND CONTROL SYSTEM FOR DEA SCHEDULE II-V MEDICINES

(57) Abstract: The present invention provides compositions and methods for synthesizing labeled drugs. The present invention further provides methods for preventing or stopping prescription drug abuse for all agents registered as a Drug Enforcement Agency (DEA) schedule II through schedule V medications. According to the present invention, methods are provided for monitoring patient compliance with prescribed drug treatment. The present invention also provides methods for facilitating a replacement prescription when a patient is left without access to their prescribed drug. Furthermore, the present invention provides a method to improve employee compliance with an employer's drug policies via either a voluntary or compulsory system for enhanced drug testing.



WO 2006/091885 A3

A REGISTRY METHOD AND CONTROL SYSTEM FOR DEA SCHEDULE II-V MEDICINES

This application claims priority to U.S. provisional application No. 60/656,232, filed February 24, 2005, the contents of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to compositions and methods for synthesizing labeled drugs. The present invention further relates to methods for preventing or stopping prescription drug abuse for all agents registered as a Drug Enforcement Agency (DEA) schedule II through schedule V medications. Further, the present invention provides methods for monitoring patient compliance with prescribed drug treatment. The present invention also provides methods for facilitating a replacement prescription when a patient is left without access to their prescribed drug. Furthermore, the present invention provides a method to improve employee compliance with an employer's drug policies via either a voluntary or compulsory system for enhanced drug testing.

BACKGROUND

Abuse of prescribed drugs such as benzodiazepines, amphetamines, amphetamine-like drugs, and opioid narcotics pose a major health risk and numerous enforcement problems in the United States and worldwide.

Benzodiazepines are anxiolytic (anxiety-relieving), hypnotic (sleep-inducing) and increase a patient's seizure threshold. Benzodiazepines are prescribed for medical conditions including anxiety, insomnia, alcohol withdrawal, seizures and as anesthetic agents given prior to and during surgery. The class of benzodiazepines contains many different medications. A partial list includes: midazolam (Versed), triazolam (Halcion), alprazolam (Xanax), lorazepam (Ativan), chlordiazepoxide (Librium), diazepam (Valium), bromazepam (Lexotan), flunitrazepam (Rohypnol, the "date-rape" drug), flurazepam (Dalmane), nitrazepam (Mogadon), oxazepam (Serenid), and temazepam (Restoril, Normison, Euhypnos). Benzodiazepines act on the central nervous system through interactions with gamma amino butyric acid (GABA) receptors. A physician, or para-professional, must hold a current and valid DEA certificate and be in good standing to prescribe a benzodiazepine. Benzodiazepines, while widely prescribed for a number of indications, are especially prone to substance abuse because they are rapidly acting anxiolytic agents.

The DEA recognizes the high propensity for abuse of benzodiazepines and has thus classified benzodiazepines as schedule IV medications. Benzodiazepine abusers often engage in "doctor-shopping," i.e., obtaining overlapping benzodiazepine prescriptions from different physicians. Doctors' prescriptions are the primary source of illicit benzodiazepines (Ashton H, Drugs and Dependence. 2002;197-212 (Harwood Academic Publishers)). Benzodiazepines are

often mixed with alcohol and commonly form part of a polysubstance abuse pattern, which can include heroin, opioids, cocaine and amphetamines (*see* Ashton). When benzodiazepines are mixed with alcohol, the intoxicating effects are not merely additive, but synergistic, and pose significant additional safety risks to individuals operating motor vehicles, passengers in their vehicles and those who share the road with them.

Amphetamines are used to treat medical conditions including Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, depression, and historically were used as appetite suppressants or weight loss medications. The family of compounds derived from amphetamine (Benzedrine) include dextroamphetamine (Dexedrine), methamphetamine (Desoxyn), benzphetamine (Didrex) and a number of others.

Methylphenidate (Ritalin) is an amphetamine-like drug prescribed for the treatment of the same disorders as amphetamines, perhaps with a somewhat lower probability of producing addictions. Both methylphenidate and its analogues, as well as the amphetamines and their analogues, are frequently prescribed to children and unfortunately are often used and abused by older siblings and others. On many college campuses, university students have found that crushing and snorting methylphenidate and amphetamines can produce cocaine-like euphoria.

Long-term, high dosage use of amphetamines and amphetamine-like drugs can result in symptoms of anxiety, panic, hallucinations and paranoia. Because these agents are sympathomimetic, they also act to increase heart rate, blood pressure and, at times, insomnia. Amphetamines and amphetamine-like drugs are extremely psychologically addictive because they increase brain dopamine levels and specifically target the brain's reward center, i.e., the *nucleus accumbens*.

A publication, Monitoring the Future Survey (MTF), funded by the National Institute on Drug Abuse, National Institutes of Health, and Department of Health and Human Services assesses the extent of drug use among adolescents and young adults in the United States. The 2003 MTF data on annual use indicate that 2.6% of 8th-graders abused Ritalin, as did 4.1% of 10th-graders and 4.0% of 12th-graders.

Opioids are commonly prescribed for their effective analgesic properties. Some of the medications that fall within this class include morphine, codeine, oxycodone (OxyContin), propoxyphene (Darvon), hydrocodone (Vicodin), hydromorphone (Dilaudid), and meperidine (Demerol). In addition to their pain-relieving properties, some of these drugs - for example, codeine and diphenoxylate (Lomotil) - can be used to relieve coughs and diarrhea. Long-term use of opioids can lead to physical dependence and addiction.

The methods of the present invention can stop or prevent prescription drug abuse because a patient is denied access to a second, overlapping prescription and doctor-shopping is effectively


thwarted. Prevention of drug abuse can be especially beneficial to the individual and society because of the high rates of relapse following treatment for drug abuse. For example, the rate of relapse following benzodiazepine detoxification has been reported to be over 90 percent (Seivewright N and Dougal W. Drug Alcohol Depend. 1993;32:15-23; Seivewright et al., Int J Drug Policy. 1993;4:42-48).

Centralized databases for recording and monitoring prescription medications have been proposed, see, e.g., U.S. Patent No. 6,687,676. Recordation in a database alone (without drug labeling) does not address the problems of abuse in which the abuser receives drug from a third party, unauthorized provider (e.g., a friend, a drug dealer), or an unscrupulous or unknowing provider (e.g., an unknowing doctor). Use of a database alone, would not allow a prescriber to discern whether the abuse is occurring due to medications supplied by a third party or unscrupulous/unknowing provider because medication from the two sources can not be differentiated. The methods of the present invention would allow identification of the source of the illicit medication because any unlabeled medication in the patient's tissue or body fluid is evidence of abuse.

SUMMARY OF THE INVENTION

The present invention relates to labeled drugs, methods for synthesizing labeled drugs and pharmaceutical compositions including labeled versions of DEA schedule II to V drugs. In aspects of the present invention, a labeled drug prescription is recorded in a registry. The present invention further relates to methods for preventing or stopping prescription drug abuse. Further, the present invention provides methods for monitoring patient compliance with prescribed drug treatment. The present invention also provides methods for facilitating replacement drug prescription when a patient is left without access to their prescribed drug.

In one embodiment, labeled benzodiazepines according to the present invention are represented by general Formula I as follows:



I

wherein,

At least two of the atoms of the structure are present as isotopes ^2H , ^{13}C , ^{15}N , or ^{18}O ;


R_1 is selected from chlorine, fluorine and nitro;


R₂ is selected from hydrogen, fluorine, or chlorine;

R₃ is selected from hydrogen, deuterium, carboxy (-COOH) or hydroxy;

R₄ is selected from no substituent or oxygen;


X₁ is selected from oxo, ¹⁸oxo, sulphur (=S) or aminomethyl (-NHCH₃);

X₂ is selected from no substituent, hydrogen, methyl, -CH₂CH₂N(CH₂CH₃)₂, trifluoroethyl (-CH₂CF₃), or methylenecyclopropyl (); or



X₁ and X₂ together represent the bridge ; and


when X₂ is no substituent or X₁ is amino methyl (-NHCH₃), there is a double bond between nitrogen-1 and carbon-2 and a single bond between carbon-2 and X₂; and



when X₁ is oxo or ¹⁸oxo, or X₁ and X₂ together represent the bridge , there is a single bond between nitrogen-1 and carbon-2 and a double bond between carbon-2 and X₂;

and pharmaceutically acceptable salts and solvates, and mixtures thereof.

Labeled amphetamines according to the present invention are represented by general Formula II:




wherein

At least one of the atoms of the structure are present as isotopes ²H, ¹³C or ¹⁵N;


R₅ is selected from hydrogen or methyl; and

pharmaceutically acceptable salts and solvates, and mixtures thereof.

More particularly, the present invention includes labeled amphetamines:




In another aspect, the present invention includes labeled methylphenidate according to the following structural formula (III):

**III**

wherein

at least one of the atoms of the structure are present as isotopes ^2H , ^{13}C or ^{15}N ; and pharmaceutically acceptable salts and solvates, and mixtures thereof.

In yet another aspect, the present invention includes labeled opiates according to structural formula **IV**:

**IV**

wherein

at least one of the atoms of the structure are present as isotopes ^2H , ^{13}C , ^{15}N , or ^{18}O ;

R_1 is selected from hydrogen, deuterium, $-\text{OH}$, or ^{18}OH ;

R_2 is selected from hydrogen or deuterium;

R_3 is selected from hydrogen or deuterium; or

R_2 and R_3 are not present and there is a C-C double bond between carbon 2 and carbon 3;

R_4 is selected from hydrogen or deuterium;


R_5 is selected from $-\text{OH}$ or ^{18}OH ; or

R_4 and R_5 together form oxo ($=\text{O}$) or ($=^{18}\text{O}$);

R_6 is selected from H or CH_3 ; and

pharmaceutically acceptable salts and solvates, and mixtures thereof.


In yet another aspect, the present invention includes labeled methadone,



wherein

the labeled methadone comprises at least one isotopic label independently selected from ^2H , ^{13}C , ^{15}N , and ^{18}O .


In yet another aspect, the present invention includes labeled fentanyl,



wherein

the labeled fentanyl comprises at least two isotopic labels independently selected from ^2H , ^{13}C , ^{15}N , and ^{18}O .

In yet another aspect, the present invention includes labeled zolpidem,




wherein

the labeled zolpidem comprises at least one isotopic label independently selected from ^2H , ^{13}C , and ^{15}N , and

pharmaceutically acceptable salts thereof.


In yet another aspect, the present invention includes labeled buprenorphine,



wherein

the labeled buprenorphine comprises at least one isotopic label independently selected from ^2H , ^{13}C , and ^{15}N .

In yet another aspect, the present invention includes labeled tramadol,



wherein

the labeled tramadol comprises at least one isotopic label independently selected from ^2H , ^{13}C , and ^{15}N .

In one embodiment of the invention, a method for preventing drug abuse is provided wherein a prescriber identifies a patient as a potential abuser, prescribes a single, double, triple or higher multiple of a labeled drug to the potential abuser, records the prescription on a national registry, tests a tissue or body fluid (e.g., urine or blood) of the potential abuser for the presence of unlabeled drug, and identifies an abuser as an individual who tests positive for unlabeled drug.

In another embodiment of the invention, a method for monitoring compliance with prescribed drug treatment is provided wherein a prescriber prescribes a drug product in which one or more of the atoms has been replaced with a labeled atom. According to the invention, one, two, three or more atoms of a drug product may be replaced with a labeled atom to enable rapid identification of the product. In another embodiment, a drug product that has been labeled on two, three or more atoms is administered to a patient, the prescription is recorded on a national registry, and a tissue or body fluid (e.g., urine or blood) of the patient is thereafter tested for the presence of labeled and unlabeled drug. The test result identifies a non-compliant patient as an individual who tests negative for the prescribed labeled drug.

The present invention further provides a method in which a prescriber prescribes a drug that has been single, double or triple labeled and wherein the patient is unaware of the number of labels

on the prescribed drug; the prescriber records the prescription in a registry; the patient is tested for the presence of unlabeled drug and labeled drugs having one, two, three or more labels; and a provider refuses to re-prescribe the drug to a patient testing positive for unlabeled drug or labeled drug having a number of labels different from the prescribed labeled drug.

The invention further comprises a method for prescribing a labeled controlled drug to a patient, which includes the steps of:

- (a) creating a drug registry containing information on prescriptions written for controlled drugs and the identity of the patient receiving such prescriptions,
- (b) recording all controlled drug prescriptions in the registry,
- (c) interrogating the drug registry for information on the patient, and
- (d) prescribing a labeled controlled drug to a patient only if the patient does not have an unexpired prescription for the same controlled drug or another controlled drug of the same class (e.g., the controlled drug and the another controlled drug are both opioids) recorded in the registry.

In an embodiment of the invention, the results of a test on a patient's tissue or body fluid for the presence of labeled or unlabeled drug is recorded on the registry.

In another aspect of the present invention, a method is provided for prescribing a labeled controlled drug to a patient, which includes the steps of:

- (a) creating a drug registry containing information on prescriptions written for controlled drugs and the identity of the patient receiving such prescriptions;
- (b) recording all controlled drug prescriptions and patient identities in the registry,
- (c) interrogating the drug registry for information on the patient,
- (d) testing the patient's tissue or body fluid for the presence of labeled or unlabeled controlled drug, and
- (e) prescribing a labeled controlled drug to a patient only if the patient does not have:
 - (i) a positive test result for an unlabeled controlled drug or a labeled controlled drug that is not recorded on the registry, or
 - (ii) an unexpired prescription for the same controlled drug recorded in the registry.

In a further aspect of the present invention, a method is provided for prescribing a labeled controlled drug to a patient, which includes the steps of:

- (a) creating a drug registry containing information on prescriptions written for controlled drugs and the identity of the patient receiving such prescriptions,
- (b) recording all controlled drug prescriptions in the registry,
- (c) interrogating the drug registry for information on the patient,
- (d) comparing a prescription for a labeled controlled drug with the registry information on the patient; and

(e) issuing the prescription only if the patient does not have an unexpired prescription for the same controlled drug recorded in the registry.

A drug can be labeled with a stable isotope according to the methods of the present invention by identifying suitable sites for isotope substitution such that substitution does not affect the activity of the drug. Following identification of a suitable substitution site(s), isotopes are substituted onto the drug by methods well known in the art as disclosed in, for example, Voges et al., Proceedings of the International Symposium, 5th Strasbourg, June 20-24 (1995):1-26; and Mertel H, Drug Fate and Metabolism 1979;3:133-191.

Synthesis of a labeled drug according to the methods of the present invention includes incorporation of isotopically labeled fragments of a drug that can be derived from commercially available reagents containing one or more heavy atom isotopic labels with greater than 90% isotopic purity. The isotopic labels are incorporated at metabolically stable sites of the drug so that they are retained on the compound while it is in the tissues or body fluids of a patient (e.g., the labels are retained on the compound when the compound is in the blood stream or when it passes from the body in the urine). Stable isotope labels ²H, ¹³C, ¹⁵N, ¹⁷O, ¹⁸O, ³³S, ³⁴S, and ³⁶S are preferred. Especially preferred stable isotope labels are ¹³C, ¹⁵N, ¹⁷O and ¹⁸O. The cost of synthesizing labeled drugs according to the present invention can be contained by selecting drugs, which are dosed in small amounts of active agent (i.e., less than 250 mg). Cost can further be contained by the economies of scale involved when large amounts of labeled drug are produced.

The present invention provides a method for identifying a non-compliant patient who does not comply with a prescription for medication, which includes the steps of:

- (a) prescribing a medication to a patient for a period of time comprising a first predetermined interval and a second predetermined interval wherein the first predetermined interval and second predetermined interval are consecutive;
- (b) providing the patient with a supply of the medication adequate to cover the period to time, wherein the supply comprises units of the medication having a plurality of different labels;
- (c) instructing the patient to self-administer the labeled units having a first label during the first predetermined time;
- (d) instructing the patient to self-administer the labeled units having a second label during the second predetermined time, the second label being different from the first label;
- (e) testing the patient for the presence of the first label during the second predetermined interval;
- (f) testing the patient for the presence of the second label during the second predetermined interval; and

(g) identifying a patient testing negative for the presence of the first label and the second label as non-compliant with the prescription medication for the period of time.

In a preferred embodiment, the period of time is about one month.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the synthetic pathway for double isotope labeled lorazepam.

Figure 2 shows the synthetic pathway for triple isotope labeled lorazepam.

Figure 3 shows the synthetic pathway for triple isotope labeled oxazepam.

Figure 4 shows the synthetic pathway for triple isotope labeled clonazepam.

Figure 5 shows the synthetic pathway for isotope labeled methylphenidate.

Figure 6 shows the synthetic pathways for single and double isotope labeled codeine.

Figure 7 shows the synthetic pathways for single, double and triple isotope labeled oxycodone.

Figure 8 shows the synthetic pathways for single, double and triple isotope labeled hydrocodone.

Figure 9 shows the synthetic pathway for double labeled dextroamphetamine

Figure 10 shows the synthetic pathway double labeled levamphetamine

Figure 11 shows the synthetic pathways for (a) ^{13}C , ^{15}N -methamphetamine, (b) ^{13}C -methamphetamine, and (c) ^{15}N -methamphetamine.

Figure 12 shows the synthetic pathway for single labeled methadone.

Figure 13 shows the synthetic pathway for single and double ^2H labeled morphine.

Figure 14 shows the synthetic pathway for single, double, and triple ^2H labeled hydromorphone.

Figure 15 shows the synthetic pathway for ^2H labeled and ^{13}C , ^{15}N labeled zolpidem.

Figure 16 shows the synthetic pathway for double ^2H labeled buprenorphine.

Figure 17 shows the synthetic pathway for various ^{13}C labeled tramadol.

DETAILED DESCRIPTION

Definitions

As used herein, “drug,” “schedule drug,” “controlled drug,” “controlled pharmaceutical agent” or “controlled substance” refers to a prescribed medication having the potential for abuse (i.e., a DEA schedule II through V medication). A drug according to the present invention includes, for example, medications in the benzodiazepine, amphetamine, amphetamine-like, and opioid classes.

As used herein, "label" refers to a tag or marker that is added onto or made part of the molecular structure of a drug, which permits a labeled drug to be distinguished from an unlabeled drug in an individual's tissue or body fluid but does not affect the pharmacologic activity of the drug. A preferred label according to the present invention is a stable isotope.

A "labeled drug" as used herein refers to a drug having at least one label (e.g., single or double isotope labeled diazepam) or a mixture of a drug having different labels in a specified ratio (e.g., a mixture of single labeled diazepam and double labeled diazepam in a 9:1 ratio).

As used herein, the term "abuse" refers to use of a drug (e.g., a benzodiazepine) in a greater than prescribed amount or frequency. An "abuser" is an individual who abuses a drug.

A "provider," as used herein is a doctor or anyone legally authorized to prescribe a drug, e.g., a benzodiazepine.

A "prescriber," as the term is used herein, is a provider who has written a prescription for a drug, e.g., a benzodiazepine, for a particular patient.

Labeled drugs

According to the present invention, a drug is labeled so that it can be identified when a specimen of a tissue or body fluid is removed from a patient receiving the labeled drug (i.e., by assaying in a sample of the patient's tissue or body fluid) and readily distinguished from an unlabeled version of the same drug. More particularly, the drug is labeled to contain an isotopic label(s) at a metabolically stable position(s) such that the labeled drug has the same biological effects as unlabeled drug. The isotopes according to the present invention are stable and inert. Preferably, the isotopes are rare. Isotopes according to the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, and sulfur (e.g., 2H , 13C , 15N , 17O and 18O).

A labeled drug according to the present invention can be selected and synthesized by a method, which includes the steps of:

- (a) selecting a drug that is medically useful but can be abused (i.e.: any of the schedule II through V drugs);
- (b) selecting atoms in the drug compound that are metabolically stable, i.e., atoms that are retained in the drug compound when the drug is in the blood stream and urine;
- (c) selecting a known synthesis for the drug that includes reagents that allow the addition of non-radioactive isotope labels at an intermediate step in the synthesis;
- (d) adding the labeled reagent;

wherein a labeled drug is synthesized.

Introduction of the label late in the synthesis is more cost effective than introduction of the label early in the synthesis of the labeled drug.

The isotope labels should be inserted with high fidelity (about 90% or greater). Preferably, the isotopically labeled reagents are commercially available with high purity of the isotope label. Isotopically labeled reagents containing 2H , 13C , 15N , 17O , and 18O are preferred. One isotope label in a drug can be used according to the present invention. More than one isotope label in a drug is preferred because the mass signature of the labeled drug will be more distinct for a drug with more than one label compared to a drug with one label.

Different labeled versions of the same drug can be mixed together to create uniquely identifiable mixtures. Thus, a very large number of uniquely identifiable isotope formulations can be created. For example, singly labeled oxycodone can be mixed at a 9:1 ratio with doubly labeled oxycodone, this would provide a mass signature in a drug test that would make this 9:1 mixture distinguishable from an 8:2 or 7:3 mixture. The only limit to the number of uniquely identifiable labeled formulations is the precision to which mass spectrometry can distinguish between isotope mixtures. The ratio of the labeled versions of a drug can be used as a code in conjunction with the national registry system that is part of the present invention.

The present invention provides labeled drugs and methods for synthesizing labeled drugs. A preferred label is a stable isotope. In an embodiment of the invention, it is advantageous to include at least one isotope label in a drug. The inclusion of isotopes in a drug increases the cost of synthesis, which can discourage the production of labeled illicit or "street" drugs.

Preferred labeled drugs according to the present invention are labeled drugs in the benzodiazepine, amphetamine, amphetamine-like (e.g., methylphenidate), and opioid class.

Registering a labeled drug

A registry according to the present invention is a database accessible to providers of drugs wherein data relating to the prescription of a labeled drug can be recorded and accessed by a provider or pharmacist. The registry includes a host system capable of selectively receiving, storing and dispensing prescription information; and a plurality of provider systems remote from the host system, which are capable of receiving and inputting prescription information into the host system. The provider system is also capable of retrieving prescription information from the host system. The registry can be accessed, for example, using a public telephone line with a coded connection (e.g., a password). The registry is constructed to protect patient privacy and is preferably compliant with existing law relating to patient privacy and right of access (e.g., Health Insurance Portability and Accountability Act ("HIPAA")). Access to a registry according to the present invention is limited to providers and, optionally, pharmacists, as well as any other individuals authorized by law (e.g., law enforcement officers). Methods for ensuring privacy are well known and include, for example, providing unique patient identifiers. For example, when a patient enters the registry he is assigned a unique identifying number or alphanumeric code that can

be used to uniquely identify him and to distinguish him from other registry participants. Construction and maintenance of a registry according to the present invention is well known as provided in, for example, U.S. Patent No. 6,687,676.

The data required to be entered by a prescriber is preferably kept to a minimum to encourage provider compliance. Such minimum data includes a patient's name or identifier, a prescriber's name or identifier, the start date of the prescription (i.e., the date the drug is dispensed), the drug prescribed, the dosage and frequency, duration of treatment, and the indication for the prescription. In an embodiment of the invention, a patient would have to show a provider, as well as a pharmacist, a valid state or federal form of identification in order to obtain and fill a prescription. Additional forms of identification can include, for example, unique identifiers such as fingerprints, retinal scans, DNA fingerprinting or other biometric identifiers. A unique identifier decreases the likelihood of a patient submitting multiple identities within the registry system.

Any physician can interrogate the registry in order to determine if a new patient had previously received a prescription from another doctor for the same DEA schedule II to V drug. The interrogation can be via the patient's number or through use of the patient's assigned "identifier" or password on the system.

In an embodiment of the present invention, a pharmacist can access the registry, and a labeled drug prescription will not be filled and dispensed unless the prescription has been recorded in the registry.

In another embodiment of the present invention, a pharmacist can access the registry, and a labeled drug prescription will not be dispensed for a patient if a current labeled drug prescription for the patient appears in the registry. According to this aspect of the present invention, concurrent dispensing of the same or similar drugs can be prevented.

In another aspect of the present invention, a pharmacist can access the registry and record in the registry the date, and optionally the time, when a drug prescription is being filled. This will "start the clock" on the prescription

Detecting a labeled drug

An isotopically labeled drug can be detected and distinguished from an unlabeled drug by any method, which can detect labeled and/or unlabeled drug in an individual's tissue or body fluid (e.g., blood or urine) and distinguish the molecular weight of the labeled and unlabeled drug. In an aspect of the invention, a detection method can distinguish drugs having different labels (e.g., one isotope label versus two isotope labels versus three isotope labels). In another aspect of the invention, a detection method can distinguish drugs containing different mixtures of labels (e.g., a 9:1 mixture of singly and doubly labeled oxycondone versus a 1:1 mixture of singly and doubly labeled oxycondone).

A labeled drug can be distinguished from unlabeled drug by, for example, mass spectrometry, nuclear magnetic resonance, gas chromatography/mass spectrometry (GC/MS), and liquid chromatography/mass spectrometry (LC/MS).

Detection of labeled and unlabeled drugs using GC/MS or LC/MS would be carried out on a sample of a few milliliters of blood or urine or some other matrix such as sweat, saliva, meconium, or a nail. Prior to GC/MS or LC/MS a sample preparation step is often carried out that may involve cleavage of conjugates, isolation, and derivatization, preceded or followed by cleanup steps. After the sample preparation step, an isolation step involving liquid-liquid extraction (LLE) or by solid-phase extraction (SPE) is carried out to extract the organic components from the prepared sample. One method of extraction is to insert a Twister™ stir bar into the prepared liquid sample and stir for a few minutes. The stir bar is removed, washed with water, dried and heated to volatilize the organics. The volatile organic compounds are injected into a GC/MS and run for about 30 minutes.

Gas chromatography (GC) separates drugs in a sample by passing the sample through a column with a stream of helium gas. The inside surface of the column is coated with wax. The wax slows down the drugs as they pass through the column so that some drugs take longer than others to reach the end of the column. As the drugs exit the column, the mass spectrum detector records the fragmentation fingerprint of the drugs. Drug identification is based on its transit time through the column and molecular fragmentation fingerprint. These two unique characteristics provide precise identification (*See Forensic Applications of Mass Spectrometry*, by Jehuda Yinon ISBN: 0849382521; *Advances in Forensic Applications of Mass Spectrometry*, by Jehuda Yinon, ISBN: 0849315220).

Labeled and unlabeled drug emerge from the gas chromatograph at the same time, but are distinguishable by mass spectroscopy. For example, the mass of unlabeled alprazolam ("rA") is 308 Daltons. Using the technique of gas chromatography - mass spectrometry, unlabeled alprazolam is detected as a mass envelope of m/e: 308.08 (100.0%), 310.08 (32.2%), 309.09 (18.5%), 311.08 (6.4%), 310.09 (1.6%), 309.08 (1.5%). Under the same conditions, singly labeled alprazolam is detected with the same retention time as unlabeled alprazolam but with a mass envelope of m/e: 309.09 (100.0%), 311.09 (32.2%), 310.09 (19.9%), 312.09 (6.0%), 311.10 (1.6%). The fragment of labeled alprazolam will be detected with the largest peak at m/e 274.11. If LC/MS is used to detect rA, under acidic conditions rA will be detected in the protonated form and the m/e envelope will be shifted up by one mass unit (m+1)/e: 309.09 (100.0%), 311.09 (32.2%), 310.09 (19.9%), 312.09 (6.0%), 311.10 (1.6%). Under these same conditions, singly-labeled alprazolam will also be shifted by one mass unit (m+1)/e: 310.09 (100.0%), 312.09

(32.2%), 311.09 (19.9%), 313.09 (6.0%), 312.10 (1.6%). These small differences in mass are easily distinguished by mass spectrometry.

A labeled drug according to the present invention contains one or more stable isotopes. A stable isotope includes, for example, hydrogen 2 (^2H), carbon 13 (^{13}C), nitrogen 15 (^{15}N), oxygen 17 (^{17}O), oxygen 18 (^{18}O), sulphur 33 (^{33}S), sulphur 34 (^{34}S), sulphur 36 (^{36}S). Stable isotopes of other elements such as chlorine and bromine can also be used but they are less commonly found in drugs of abuse. The compositions and methods of the present invention provide for substitution of hydrogen (^1H) with ^2H , carbon (^{12}C) with ^{13}C , nitrogen (^{14}N) with ^{15}N , and oxygen (^{16}O) with ^{17}O or ^{18}O , and sulphur (^{32}S) with ^{33}S or ^{34}S or ^{36}S , such that a drug is labeled at metabolically stable sites.

A labeled drug according to the present invention can also contain mixtures of labeled drug containing two or more different labeled versions of the same drug in a specified ratio (e.g., a mixture of single and double labeled drug in a ratio of 2:1).

Methods of preventing or stopping drug abuse

According to the present invention, drug abuse can be prevented by prescribing a labeled drug to a patient; recording a patient identifier and the labeled drug prescription in a registry accessible to providers; testing a fluid or tissue sample from the patient for the presence of unlabeled drug or isotopically labeled drug containing a different number of isotopic labels than was originally prescribed. These patients would be identified as being non-compliant with their responsibility to take only medication prescribed by a single provider. Options such as detoxification and drug treatment could at that point be offered.

In an aspect of the present invention, a patient can be identified as non-compliant if the patient is tested and a mixture of labeled drug is identified in the patient's tissues that is different than the formulation that the patient was prescribed.

In an example according to the present invention, a doctor (i.e., a prescriber) prescribes a labeled drug (e.g., triple-isotope labeled diazepam) to a patient for the treatment of a medical condition (e.g., alcohol withdrawal). In an embodiment of the invention, a prescriber can select a labeled drug from among a group of the same drug having different labels (e.g., single- or double-isotope labeled diazepam); according to this embodiment, the particular label selected is not disclosed to the patient. Further, according to the invention, the doctor or his staff records the labeled drug prescription in a registry by accessing the registry using, for example, a personal computer in the doctor's office. The data included in the recordation includes, for example, the patient's name or unique identifier, the doctor's name, the prescribed drug, the date of the prescription, the dosage, frequency and duration of treatment, and the medical indication for the

prescription. In an embodiment of the invention, a pharmacist accesses the registry to confirm recordation of the prescription prior to dispensing the drug.

In an embodiment of the present invention, the dispensing of isotopically labeled medication, whether it be singly, doubly or multiply labeled moieties, can be double-blind with respect to the prescribers as well as the patients. Such double-blind dispensing can prevent unscrupulous providers from intentionally colluding with patients to receive medication outside of the registry system.

In an aspect of the present invention, an employer having an employee's consent can ensure that the employee is receiving a prescription drug as prescribed by using the registry system. By using only isotopically labeled medication, the employer can know with certainty that an employee is only receiving the medication in the intended quantities. This would prevent an employee who revealed that he is taking a medication from receiving quantities of that medication beyond the scope of what the prescriber of the medication intends.

Further, according to the invention, insurance companies or third party payers can be ensured that the individual who is covered by the policy is only receiving schedule drug within the purview of the registry. This would allow an insurer to investigate whether a schedule drug could be exacerbating or disguising an underlying medical condition via overuse of the prescribed agent.

Further, according to the invention, if the patient visits the same doctor or another doctor (a provider, but not the prescriber) seeking a prescription for a drug that they are currently being prescribed, or a similar drug (e.g. if they are currently taking labeled oxycontin the prescriber may want to avoid prescribing additional opiates), the doctor (either the non-prescribing provider or the prescriber) can access the registry and determine the patient's eligibility to receive the requested drug. According to an embodiment of the invention, the doctor refuses to write a prescription for the drug if a current, filled prescription for the labeled drug is recorded in the registry. In another embodiment of the invention, the doctor tests the patient for unlabeled and labeled drug, and refuses to write a prescription for the patient with a recorded prescription for labeled drug who tests positive for unlabeled drug. In a further embodiment, a provider refuses to write a prescription for a drug if the patient tests positive for a labeled drug (e.g., triple-isotope labeled diazepam) different from the recorded prescribed labeled drug (e.g., double-isotope labeled diazepam).

Methods of monitoring patient compliance

According to the present invention, a patient can be monitored for compliance with prescribed drug treatment by prescribing a labeled drug to a patient; recording the labeled drug prescription in a registry accessible to providers; testing a fluid or tissue sample from the patient for the presence of labeled and unlabeled drug; and identifying as non-compliant a patient testing

negative for labeled drug. This can prevent an individual from registering with the database, not take the prescribed medication, and furnish the prescribed medication to a third party.

In an example, according to the present invention, a doctor (i.e., a prescriber) prescribes a labeled drug (e.g., triple-isotope labeled diazepam) to a patient for the treatment of a medical condition (e.g., alcohol withdrawal). In an embodiment of the invention, a prescriber can select a labeled drug from among a group of the same drug having different labels (e.g., single- or double-isotope labeled diazepam). According to this embodiment, the particular label selected is not disclosed to the patient. Further, according to the invention, the doctor or his staff records the labeled drug prescription in a registry by accessing the registry using, for example, a personal computer in the doctor's office. The data included in the recordation includes, for example, the patient's name or unique identifier, the doctor's name, the prescribed drug, the date of the prescription, the dosage, frequency, the duration of treatment, and the medical indication for the prescription. In an embodiment of the invention, a pharmacist accesses the registry to confirm recordation of the prescription prior to dispensing the drug.

Further, according to the invention, the patient visits the same doctor or another doctor (a provider, but not the prescriber). The doctor (either the non-prescribing provider or the prescriber) accesses the registry and tests the patient for unlabeled and labeled drug. The patient is identified as non-compliant if the patient tests negative for the recorded labeled drug.

Methods for facilitating replacement drug prescriptions

It is not uncommon for patients with prescribed drugs to be left without access to their prescription drugs and in need of a replacement prescription from a provider who was not the prescriber. For example, a traveler who forgot to pack his prescription drug can be on a trip far from home without a means of contacting his prescriber. In such situations, the traveler can visit a provider who was not the prescriber to obtain a replacement prescription. The provider may be reluctant to write such a prescription because of the possibility that the traveler is doctor-shopping.

The present invention provides a method for facilitating replacement drug prescription by a provider. According to the invention, the provider can access a registry and prescribe a replacement drug prescription to a patient with a current labeled drug prescription recorded on the registry in the situation where the labeled drug prescribed and recorded in the registry is not immediately available to the patient.

Methods for safely tapering a drug

The present invention provides a method for safely tapering a drug. For example, a patient who is addicted to a drug (e.g., diazepam) sees a provider. The provider prescribes a tapering dosage regimen of labeled drug. For example, a patient would be dispensed a one week supply of isotopically labeled diazepam 10 mg per day, followed by a one week supply of isotopically labeled

diazepam 7.5 mg per day, followed by a one week supply of isotopically labeled diazepam 5.0 mg per day and then a final one week supply of isotopically labeled diazepam 2.5 mg per day before the patient has been safely tapered from this dependency-inducing medication. To ensure compliance, a national database would contain a description of the patient's tapering regimen. According to the present invention, each dosage of drug in the regimen has a different label (e.g., the 10 mg diazepam is triple isotope labeled and the 5 mg diazepam is double isotope labeled). During the course of the taper regimen the tissue or body fluid of the patient is tested for labeled and unlabeled drug. A positive test for the labeled drug corresponding to the appropriate drug in the taper regimen at the time of testing indicates that the patient is properly adhering to the taper regimen (e.g., the patient tests positive for triple isotope labeled diazepam on a day when he should be taking triple labeled diazepam). A positive test for an unlabeled drug or a labeled drug that should not be present in the patient's tissue or body fluid at the time of the test indicates that the patient is not properly adhering to the taper regimen (e.g., the patient tests positive for double labeled diazepam on a day when he should be taking triple labeled diazepam). A negative test for labeled drug during the course of the taper regimen is another indication that the patient is not adhering to the taper regimen.

Also, according to the present invention, a more gradual taper can be achieved by mixing differently labeled drugs (e.g., a double labeled drug with a triple labeled drug) at different ratios (e.g., 9:1, 8:2, 7:3, ..., 1:1, ... 9:1) while at the same time steadily decreasing the total amount of drug in each dose. During the course of the taper regimen the tissue or body fluid of the patient is tested for the two labeled drugs. A positive test corresponding to the proper ratio of the two labeled drugs in the specimen indicates that the patient is properly adhering to the taper regimen (e.g., the patient tests positive for 80% triple isotope labeled diazepam and 20% double isotope labeled diazepam on a day when he should be 80% of the way through the taper regimen). A positive test for an unlabeled drug or a labeled drug that should not be present in the patient's tissue or body fluid at the time of the test indicates that the patient is not properly adhering to the taper regimen (e.g., the patient tests positive for double labeled diazepam on a day when he should be taking triple labeled diazepam). A negative test for labeled drug during the course of the taper regimen is another indication that the patient is not adhering to the taper regimen.

Methods for identifying a patient who is non-compliant with a prescription for medication

The present invention provides a method for identifying a non-compliant patient who does not comply with a prescription for medication. According to this method, for example, a patient is prescribed a one month supply (a "period of time") of a medication. The one month supply of medication includes, for example, a three week supply of medication units having one isotopic label per unit and a one week supply of medication units having two isotopic labels per unit. The patient

is instructed to self-administer the one label units for the first three weeks of the one month (a “first predetermined interval”) and the two label units for the fourth week on the one month (a “second predetermined interval”). At any point during the fourth week, the patient is tested for the presence of the one label unit and the two label unit. A negative test for the one label unit identifies a patient who was non-compliant with the prescription during the first three weeks of the month. A negative test for the two label unit identifies a patient who was non-compliant during the fourth week of the month. A negative test for both the one label unit and the two label unit identifies a patient who was non-compliant with the prescription during the first three weeks of the month and the fourth week of the month. According to this method, the labeled medication administered during the first predetermined interval must have a half-life sufficiently long to remain at detectable levels in a patient during the second predetermined interval.

Salts, Solvates, Prodrugs, and Stereoisomers

Typically, a pharmaceutically acceptable salt of a compound of the present invention can be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. For example, an aqueous solution of an acid such as hydrochloric acid may be added to an aqueous suspension of a compound of the present invention and the resulting mixture evaporated to dryness (lyophilized) to obtain the acid addition salt as a solid. Alternatively, a compound of the present invention may be dissolved in a suitable solvent, for example an alcohol such as isopropanol, and the acid may be added in the same solvent or another suitable solvent. The resulting acid addition salt may then be precipitated directly, or by addition of a less polar solvent such as diisopropyl ether or hexane, and isolated by filtration.

The acid addition salts of a compound of the present invention can be prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

As used herein, the term “salts” can include acid addition salts or addition salts of free bases. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include but are not limited to salts derived from nontoxic inorganic acids such as nitric, phosphoric, sulfuric, or hydrobromic, hydroiodic, hydrofluoric, phosphorous, as well as salts derived from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxyl alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and

aromatic sulfonic acids, and acetic, maleic, succinic, or citric acids. Non-limiting examples of such salts include napadisylate, besylate, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S. M. et al. "Pharmaceutical Salts," J. of Pharma. Sci., 1977; 66:1).

Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate". Solvates of the compound of the invention are within the scope of the invention. The salts of a compound of the present invention can form solvates (e.g. hydrates) and the invention also includes all such solvates.

The present invention also encompasses prodrugs of the aforementioned compounds of the present invention, i.e., compounds which release an active parent drug according to the aforementioned compounds *in vivo* when administered to a mammalian subject. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or *in vivo*, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol, sulfhydryl and amine functional groups of a compound of the present invention. Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and/or be hydrolysable under *in vivo* conditions in the human body. Suitable pharmaceutically acceptable *in vivo* hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.

A compound of the present invention can exist in numerous forms of structural isomers that may be formed as a result of tautomerism, and may exist in different ratios at equilibrium. Due to dynamic equilibrium such isomers (tautomers) are rapidly interconvertible from one isomeric form to another. The most common isomerism is keto-enol tautomerism, but equilibrium between open chain and cyclic forms are also known. It is to be understood that whenever in the present invention we refer to aforementioned compounds of the present invention,

we mean to include tautomeric forms thereof, keto-enol tautomeric, open chain-cyclic, isolated as separate isomers or existing in any other mixture of different ratios at equilibrium. The isomeric forms predominant for a particular compound of the present invention are dependent on the nature of the substituent, whether the compound exists in the free form or in the form of any of its salts, type of the salt, solvent in which the compound is dissolved, as well as pH value of the solution.

Compounds of the present invention may further exist as different geometric isomers or different stereoisomers. Isomers that differ only with regard to the arrangement of the atoms in the space around the asymmetric (stereogenic, chiral) center are called "stereoisomers". Stereoisomers that are not mirror images of each other are called diastereomers, while stereoisomers that have a mirror-image relationship, i.e. that are mirror images of each other, are called enantiomers. Each stereoisomer may be characterized by determining the absolute configuration of the stereogenic center by the use of Cahn-Ingold-Prelog priority rules and hence characterized as the R- or S-isomer. Another way of identification of stereoisomers is the measurement of the rotation of the plane of polarized light that passes through the molecule, and designating chiral molecules to be right-rotating (+) or left-rotating (-) isomers. Chiral molecules may exist in a form of single enantiomer or in a mixture of enantiomers. A mixture consisting of equal parts (+) and (-) enantiomers of a chiral substance is called racemic mixture. The present invention relates to each stereoisomer that may be shown by the aforementioned compounds of the present invention either isolated as separate enantiomers, diastereomers or existing in racemic or any other mixture thereof.

Methods for determination of stereochemical configuration, resolution and separation of stereoisomers are well known from the literature. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereomeric salts which may be separated, for example, by crystallization; formation of diastereomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. The diastereomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above.

The present invention also encompasses stereoisomers of the syn-anti type, and mixtures thereof encountered when an oxime or similar group is present. The group of highest Cahn-Ingold-Prelog priority attached to one of the terminal doubly bonded atoms of the oxime, is compared with hydroxy group of the oxime. The stereoisomer is designated as Z (zusammen = together) or Syn if the oxime hydroxyl lies on the same side of a reference plane passing through the C=N double

bond as the group of highest priority; the other stereoisomer is designated as E (entgegen = opposite) or Anti.

Compounds of the present invention may be in crystalline or amorphous form. Furthermore, some of the crystalline forms of the aforementioned compounds of the present invention may exist as polymorphs, which are included in the present invention.

Pharmaceutical Compositions

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient in a pharmaceutical formulation, e.g., when the agent is in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

Accordingly, in one aspect, the present invention provides a pharmaceutical composition or formulation comprising at least one compound of the invention or a pharmaceutically acceptable derivative thereof in association with a pharmaceutically acceptable excipient, diluent and/or carrier. The excipient, diluent and/or carrier must be "acceptable" in the sense of being compatible with the other ingredients in the formulation and not deleterious to the recipient thereof.

The term "pharmaceutically acceptable", as used in connection with compositions of the invention, refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human). Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.

The term "carrier" applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. However, since benzodiazulene salt are highly soluble, aqueous solutions are preferred. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, 18th Edition. Particularly preferred for the present invention are carriers suitable for immediate-release, i.e., release of most or all of the active ingredient over a short period of time, such as 60 minutes or less, and make rapid absorption of the drug possible.

The term “pharmaceutically acceptable derivative” as used herein means any pharmaceutically acceptable salt, solvate or prodrug, e.g. ester, of a compound of the invention, which upon administration to the recipient is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Such derivatives are recognizable to those skilled in the art, without undue experimentation. Nevertheless, reference is made to the teaching of Burger’s Medicinal Chemistry and Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives. Preferred pharmaceutically acceptable derivatives are salts, solvates, esters, carbamates and phosphate esters. Particularly preferred pharmaceutically acceptable derivatives are salts, solvates and esters. Most preferred pharmaceutically acceptable derivatives are salts and esters.

The compounds of the invention may be formulated for administration in any convenient way for use in human or veterinary medicine and the invention therefore includes within its scope pharmaceutical compositions comprising a compound of the invention adapted for use in human or veterinary medicine. Such compositions may be presented for use in a conventional manner with the aid of one or more suitable excipients, diluents and/or carriers. Acceptable excipients, diluents and carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington’s Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical excipient, diluent and/or carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as – or in addition to – the excipient, diluent and/or carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s).

Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used. For some embodiments, the agents of the present invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e. g. as a carrier, diluent or solubilizer. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO 91/11172, WO 94/02518 and WO 98/55148.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation

types. Finely divided (nanoparticulate) preparations of the compounds of the invention may be prepared by processes known in the art, for example see International Patent Application No. WO 02/00196 (SmithKline Beecham).

The tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia.

Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the agent may be combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

The compounds of the invention may also be used in combination with other therapeutic agents. The invention thus provides, in a further aspect, a combination comprising a compound of the invention or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent. The combinations may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.

When administration is sequential, either the compound of the invention or the second therapeutic agent may be administered first. When administration is simultaneous, the combination may be administered either in the same or different pharmaceutical composition.

When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of formulation. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.

The compositions may contain from 0.01-99% of the active material.

The preparation of pharmaceutical formulations may include blending, granulating, tableting and dissolving the ingredients. Pharmaceutically acceptable carriers (binders and fillers)

may be solid or liquid. Solid carriers may be lactose, sucrose, talcum, gelatine, agar, pectin, magnesium stearate, fatty acids etc. Liquid carriers may be syrups, oils such as olive oil, sunflower oil or soy bean oil, water etc. Similarly, the pharmaceutically acceptable Formulations may also contain a component for a sustained release of the active component such as e.g. glyceryl monostearate or glyceryl distearate.

Dosages

The dosage of a labeled drug according to the present invention is the same as the dosage of the corresponding unlabeled drug, e.g., labeled diazepam according to the present invention is dosed in the same amount and frequency as unlabeled diazepam.

Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. The daily dosage level of the agent may be in single or divided doses.

Methods of synthesizing a labeled drug

It will be appreciated by those skilled in the art that it may be desirable to use protected derivatives of intermediates used in the preparation of the compounds of Formulae I-IV. Protection and deprotection of functional groups may be performed by methods known in the art. Hydroxyl or amino groups may be protected with any hydroxyl or amino protecting group, for example, as described in Green T.W.; Wuts P. G. M. *Protective Groups in Organic Synthesis*: John Wiley and Sons, New York, 1999. The amino protecting groups may be removed by conventional techniques. For example, acyl groups, such as alkanoyl, alkoxycarbonyl and aryloyl groups, may be removed by solvolysis, e.g., by hydrolysis under acidic or basic conditions. Arylmethoxycarbonyl groups (e.g., benzyloxycarbonyl) may be cleaved by hydrogenolysis in the presence of a catalyst such as palladium-on-charcoal.

The synthesis of the target compound is completed by removing any protecting groups, which are present in the penultimate intermediate using standard techniques, which are well known to those skilled in the art. The deprotected final product is then purified, as necessary, using standard techniques such as silica gel chromatography, HPLC on silica gel, and the like or by recrystallization.

Synthesis of Labeled Benzodiazepines


Compounds of Formula I and pharmaceutically acceptable derivatives thereof may be prepared by the general methods outlined hereinafter, said methods constituting a further aspect of

the invention. In the following description, the groups R_1 to R_4 , X_1 , X_2 have the meaning defined for the compounds of Formula **I** unless otherwise stated.

A further object of the present invention relates to the preparation of compounds of Formula **I** according to processes comprising:

(a) For compounds of Formula **I**, wherein there is a C-N single bond between nitrogen 1 and carbon 2, X_1 is oxygen and there is a C=O double bond between X_1 and carbon 2, and X_2 is hydrogen and R_3 is hydrogen and R_4 is no substituent:

condensing of a compound of Formula **B1**:



B1


wherein

the compound **B1** can contain from zero to at least one isotopic labels;

R_1 is selected from chlorine, fluorine or nitro; and

R_2 is selected from hydrogen, fluorine, or chlorine,

with an isotopically labeled compound **B2**



B2


wherein

at least one atom labeled with “*” is a stable isotope such as ^{13}C for C, ^{15}N for N, ^{18}O for O and ^2H for H;

Y is a leaving group such as chloro, fluoro, or substituted phenyl alkoxide;


P_1 is an amine protecting group,

then removing the protecting group P_1 to produce a compound of formula **B3**:



wherein


compound **B3** contains at least two isotopic labels, and then intramolecularly dehydrating **B3** (e.g. refluxing benzene with a Dean-Stark trap) to form a compound of formula **B4**:




wherein


compound **B4** contains at least two isotopic labels.

(b) For compounds of Formula I, wherein there is a C-N single bond between nitrogen 1 and carbon 2, X₁ is oxygen and there is a C=O double bond between X₁ and carbon 2, and R₃ is hydrogen, R₄ is no substituent, and X₂ is methyl (-CH₃), -CH₂CH₂N(CH₂CH₃)₂, trifluoroethyl (-

CH₂CF₃), or methylenecyclopropyl (, comprising

treating an isotopically labeled compound **B4** with a strong base (e.g. sodium hydride), and then treating the compound with an alkyl halide such as CH₃I,


I-CH₂CH₂N(CH₂CH₃)₂, I-CH₂CF₃, or  to produce a compound of formula **B5**:

**B5**

wherein


compound **B5** contains at least two isotopic labels.

(c) For compounds of Formula **I**, wherein there is a C-N single bond between nitrogen 1 and carbon 2, X₂ is hydrogen or methyl, X₁ is oxygen and there is a C-O double bond between X₁ and carbon 2, and R₃ is hydroxy, and R₄ is no substituent, comprising reacting a compound of Formula **B5**:

**B5**

wherein

compound **B5** contains at least two isotopic labels with an electron poor peroxyacid, then treating the resulting product with a compound of formula **B6**,


**B6**

wherein


R₁ and R₂ are independently selected from C₁-C₆ alkyl, and then saponifying (i.e., hydrolysis) of the ester intermediate.

(d) For compounds of Formula I, wherein there is a C-N single bond between nitrogen 1 and

carbon 2, X₁ and X₂ together represent the bridge



substituent, comprising treating a compound of Formula B7,




B7

wherein

compound **B7** contains at least two isotopic labels,


with a base, then reacting the compound with diethylchlorophosphate and then reacting the a compound with a compound of formula B8



B8


See Walser et. al *J. Med. Chem.* (1991) **34**, 1209-1221 for methods of making triazole rings.

e) For compounds of Formula I, wherein there is a C-N double bond between nitrogen 1 and carbon 2, X₂ is no substituent, X₁ is methylamino and there is a C-N single bond between X₁ and carbon 2, R₃ is hydrogen, and R₄ is oxygen, a compound of Formula B9



B9

is treated with mCPBA to form a compound of formula B10



which is reacted with methylamine using titanium tetrachloride as a catalyst.

Preparation Methods for Labeled Benzodiazepines:


The compounds of Formula I can be prepared by the methods disclosed above using standard protocols known in the art of organic chemistry.

- a) Respecting the compounds of Formula I wherein synthesis occurs via the compounds of Formula B3, reaction can occur in the presence of base and under the appropriate conditions for dehydration and imine condensation. Appropriate bases are, for example, pyridine, NEt_3 , and Hunig's base and the reaction may be carried out in the presence of Mg_2SO_4 , molecular sieves, or under Dean-Stark conditions for removal of water from the system. The condensation to form the diazepine ring structure can take place in neat base, or in the presence of a solvent such as toluene and is normally reacted under refluxing conditions. The reaction is stirred in air or under a nitrogen atmosphere until the water has been substantially removed from the system. Upon completion, the solvents can be removed *in vacuo* and the crude product purified by recrystallization or by chromatography (e.g., silica gel or preparative HPLC). Optionally, the base can be removed by extraction with aqueous acid (e.g., ammonium chloride).
- b) Respecting the compounds of Formula I wherein synthesis occurs between the compounds of Formula B5 and B6, reaction can occur in a suitable organic solvent (e.g.: CH_2Cl_2 , CHCl_3 , dimethylformamide etc.) or by the addition of a compound of Formula B5 to the neat anhydride. Generally, the reaction is heated to an appropriate temperature (e.g., 50-80 °C) until substantial conversion has been reached. Solvent and excess anhydride can then be removed *in vacuo* or the reaction system can be extracted with aqueous acid to remove the anhydride. The crude product purified by recrystallization (e.g., in ethanol) or by chromatography.
- c) Respecting the compounds of Formula I wherein synthesis occurs between the compounds of Formula B7 and B8, reaction can occur by treating B7 (0.04 mol) in 350 mL of THF with potassium tert-butoxide (0.044 mol) and stirring under N_2 for 30 min at -10 to -5 degrees celscius. Diethyl chlorophosphate (6.6 mL) is then added and the mixture is stirred at this temperature for another 30 min. Following the addition of acetic hydrazide (3.4 g), stirring without cooling is continued for 1 h and 1-butanol (150 mL) is added. The THF and part of the 1-butanol is distilled

out of the reaction mixture over a period of 45 min. The residue is partitioned between toluene and water. The organic phase is washed with brine, dried, and evaporated.

d) Respecting the compounds of Formula **I** wherein synthesis occurs from a compound of Formula **B10**, reaction can occur by treating **B10** with methylamine in tetrahydrofuran at ice-bath temperature with a tetrahydrofuran-titanium tetrachloride complex. For reference see: Fryer and co-workers, *J. Org. Chem.* (1969) **34**, 1143-1145.


e) The compounds of Formula **B5** can be prepared by a reaction of the compounds of Formula **B11** wherein R_5 and X_2 are selected from hydrogen or methyl,

**B11**

wherein

the compound **B1** can contain from zero to at least one isotopic labels;

with an isotopically labeled compound **B2**

**B2**

wherein

at least one atom labeled with “*” is a stable isotope such as ^{13}C for C, ^{15}N for N, ^{18}O for O and ^2H for H; and

P_1 is preferably *tert*-butoxycarbonyl (Boc) or benzyloxy carbonyl (Cbz).

The coupling of **B1** and **B2** can be carried out with the carboxylic acid functionality in place or with suitably activated derivatives of carboxylic acid, followed where necessary by subsequent removal of the amino protecting group. Suitably activated derivatives of the carboxylic acid include the corresponding acid halide (preferably the acid chloride), mixed anhydride or an activated ester (e.g., a thiol ester). The reaction is preferably carried out in a suitable aprotic solvent such as a halohydrocarbon (e.g. dichloromethane) or N,N-dimethylformamide and optionally in the presence of a tertiary base such as dimethylaminopyridine (DMAP) or triethylamine, or in the presence of inorganic base (e.g. sodium hydroxide) and at a temperature within the range of 0 to 120 °C. The compounds of formulae **B1** and **B2** may also be reacted

directly in the presence of a carbodiimide such as dicyclohexylcarbodiimide (DCC) or EDC. The deprotection of the amino protecting group, if appropriate, is carried out using techniques known in the art, for example; the Cbz group can be removed with hydrogenation in the presence of a palladium catalyst on carbon, or in the presence of an aqueous or organic acid.

f) The compounds of formula **B6** are either commercially available, or can be prepared by condensation of the appropriate carboxylic acids under dehydrating conditions.

g) The compounds of Formula **B7** are prepared from the compounds of Formula **B3** under the conditions set forth for the synthesis of the Formula **I** compounds wherein the Formula **B3** compounds are employed as an intermediate.


h) Besides the above-mentioned reactions, the compounds of Formula **I** may be prepared by transforming other compounds of Formula **I** and it is to be understood that the present invention also comprises such compounds and processes. An example is set forth in above preparation method (i). An additional example could be the conversion of a Formula **I** compound wherein X_2 is hydrogen to a formula **I** compounds wherein X_2 is methyl. The reaction can be carried out in the presence of a base appropriate for nitrogen deprotonation (e.g., NaH, LDA, K_2CO_3 , NaOtBu) and subsequent quenching of the nitrogen anion with a methyl electrophile (preferably MeI).

Synthesis of labeled amphetamines

Compounds of Formula **II** and pharmaceutically acceptable derivatives thereof may be prepared by the general methods outlined hereinafter, said methods constituting a further aspect of the invention. In the following description, the group R_5 has the meaning defined for the compounds of Formula **II** unless otherwise stated.

A further object of the present invention relates to the preparation of compounds of Formula **II** according to processes comprising:

(a) for compounds of Formula **II**, wherein R_5 has the meaning of hydrogen or methyl, reducing a compound of Formula **A1**




A1

wherein

compound **A1** contains at least two isotopic labels; and

X_3 is hydroxy or oxo.


(b) Additionally, for compounds of Formula II, wherein R_5 has the meaning of hydrogen, reducing a compound of Formula A2:



A2

wherein compound A2 contains at least two isotopic labels; and the nitroalkene can be present in the E or Z form or as a mixture thereof.

(c) For compounds of Formula II, wherein R_5 has the meaning of hydrogen or methyl, reducing a compound of Formula A3




A3

wherein

compound A3 contains no or at least two isotopic labels;

in the presence of NHR_6 , wherein R_6 is selected from hydrogen or methyl

(d) For compounds of Formula II, wherein R_5 has the meaning of methyl, reducing a compound of formula A4




A4

wherein

compound A4 contains no or at least two isotopic labels.

(e) For compounds of Formula II, wherein R_5 has the meaning of hydrogen, hydrolysis of sulfinate A5



A5

wherein

compound A5 contains at least two isotopic labels.

Preparation Methods for Labeled Amphetamines:


(a) Respecting the compounds of Formula II wherein synthesis occurs via the compounds of Formula A1, reaction can occur in the presence of a reducing agent. Appropriate reducing agents are those capable of reducing a benzylic alcohol or ketone to a benzylic methylene (e.g., LiAlH_4). The reaction is carried out in an appropriate organic solvent, for example, THF, diethylether, or hexane, and at a temperature from 0 °C to 70 °C. The reaction is stirred in air or under a nitrogen atmosphere until the benzylic oxygen has been substantially reduced, and upon completion excess reducing agent can be quenched by the addition of base (e.g., NaOH). Aluminium or boron salts can be removed by filtration or aqueous extraction and the solvent can be removed *in vacuo*. The crude product can then be purified by recrystallization or by distillation.

(a) Respecting the compounds of Formula II wherein synthesis occurs via the compounds of Formula A2, reaction can occur in the presence of a reducing agent. Appropriate reducing agents are those capable of reducing a nitrostyrene to the corresponding phenethylamine (e.g., LiAlH_4). The reaction is carried out in an appropriate organic solvent, for example, THF, diethylether, or hexane, and at a temperature from 0 °C to 70 °C. The reaction is stirred in air or under a nitrogen atmosphere until the benzylic oxygen has been substantially reduced, and upon completion excess reducing agent can be quenched by the addition of base (e.g., NaOH). Aluminium or boron salts can be removed by filtration or aqueous extraction and the solvent can be removed *in vacuo*. The crude product can then be purified by distillation.

c) Respecting the compounds of Formula II wherein synthesis occurs via the compounds of Formula A3, reaction can occur in the presence of the appropriate amine base or salt, and with the appropriate reducing agent for a reductive amination (e.g., NaBH_3CN , $\text{NaBH}(\text{OAc})_3$). For example, to a solution of a compound of formula A3 in THF, a solution of methyl amine in THF and solid $\text{NaBH}(\text{OAc})_3$ are added. The reaction is stirred at an appropriate temperature (e.g., 25 °C) until the reduction is substantially complete and the reducing agent is then quenched with the addition of aqueous base. Reaction byproducts are then removed by extraction and the product can be purified by distillation.

d) Respecting the compounds of Formula II wherein synthesis occurs via the compounds of Formula A4, reaction can occur in the presence of a reducing agent. Appropriate reducing agents are those capable of reducing an *N*-formyl group to an *N*-methyl group (e.g., LiAlH_4). The reaction is carried out in an appropriate organic solvent, for example, THF, diethylether, or hexane, and at a temperature from 0 °C to 70 °C. The reaction is stirred in air or under a nitrogen atmosphere until the benzylic oxygen has been substantially reduced, and upon completion excess reducing agent can be quenched by the addition of base (e.g., NaOH). Aluminum or boron salts can be removed by filtration or aqueous extraction and the solvent can be removed *in vacuo*. The crude product can then be purified by distillation.

e) The compounds of Formula A1 can be prepared, for example, by a reacting phenyllithium (available commercially or prepared by the addition of an alkyllithium reagent to bromobenzene at low temperature (e.g., -78 °C) with a Weinreb amide of Formula A6.



A6

wherein P₁ is hydrogen or a protecting group for an amine (e.g., Boc or Cbz).

The phenyllithium reagent is slowly added to the Weinreb amide at low temperature and the reaction is then allowed to warm to room temperature. Upon substantial conversion to product, the reaction is quenched by the addition of water or aqueous acid and the product purified by recrystallization or chromatography.

f) The compound of formula A2 can be prepared by the adding nitroethane to the appropriately isotopically labeled benzaldehyde (i.e., a Henry reaction). The reaction is carried out in an organic solvent, in acetic acid, or in an organicsolvent/aqueous base biphasic mixture and in the presence of a base capable of deprotonating nitroethane (e.g., amine bases, NaOH). Additionally the reaction is performed under appropriate conditions such that the intermediate nitroaldol product is dehydrated to the nitrostyrene. The condensation can take place, for example, by heating the reaction mixture in acetic acid. The crude product can then be purified by recrystallization or chromatography.


g) Besides the above-mentioned reactions, the compounds of Formula II may be prepared by transforming other compounds of Formula II and it is to be understood that the present invention also comprises such compounds and processes. An example is set forth in above preparation method (d) wherein an isotopically labeled amphetamine can be converted to the corresponding methamphetamine by conversion to *N*-formyl amphetamine followed by reduction. *N*-formyl amphetamine can be prepared by the methods known in the art, for example, by reaction with formic acid under conditions appropriate for condensation (azotropic removal of water) or by reaction with formic acid in the presence of a peptide coupling reaction such as a carbodiimide (e.g., DCC or EDC). Additionally, the compound of Formula II wherein R₅ is methyl can be prepared from the compound of Formula II wherein R₅ is hydrogen by treatment of the latter with paraformaldehyde (or another formaldehyde equivalent known in the art) and reduction of the intermediate imine with a suitable reducing agent (e.g., LiAlH₄).

Synthesis of labeled methylphenidate

For a preparative method for the synthesis of labeled methylphenidate, refer to Figure 5 and Example 5.

Synthesis of labeled fentanyl

For the synthesis of labeled fentanyl, coupling of a compound of Formula **F1**,




wherein

F1 contains one or more ¹H, ¹³C, ¹⁸O labels; and

L is hydroxy or an appropriate leaving group (e.g., chloride, thioester)

with a compound of Formula **F2**,



When **F1** is a labeled propionyl chloride, it can be synthesized from labeled propionic acid by treating the propionic acid with oxalyl chloride. Labeled propionic acids include propionic acid (1-¹³C, 99%), propionic acid (13C3, 99%), propionic acid (METHYL-D3, 98%), propionic acid (D5, 98%), propionic acid (2,2-D2, 98%), propionic acid (2,2-D2, 98%), and propionic acid (D6, 98%), which are commercially available from Cambridge Isotope Laboratories (Andover, Massachusetts).

For examples of fentanyl synthesis, see: Reference: Brine, G. A.; Boldt, K. G.; Huang, P.-T.; Sawyer, D. K.; Carroll, F. I.; JHTCAD; J. Heterocycl. Chem.; EN; 26; 1989; 677-686.

EXAMPLES

The present invention is also described by means of the following examples. However, the use of these or other examples anywhere in the specification is illustrative only and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to any particular preferred embodiments described herein. Indeed, many modifications and variations of the invention may be apparent to those skilled in the art upon reading this specification and can be made without departing from its spirit and scope. The invention is therefore to be

limited only by the terms of the appended claims along with the full scope of equivalents to which the claims are entitled.

EXAMPLE 1: SYNTHESIS OF (1,2-¹³C₂, 98%) LORAZEPAM

The synthesis of double isotope labeled lorazepam was carried out using a modification of the protocol set forth in Koves, G.J. (*Journal of Radiolabeled Compounds and Radiopharmaceuticals* (1991) 29(1) 15-22) and described in detail in **Figure 1** and the following description.

Intermediate 1 (I-1): N-Cbz-(1,2-¹³C₂, 98%)-glycine

To a 500 mL three neck flask fitted with a reflux condenser, rubber septum, nitrogen adapter and magnetic stir bar will be added (U-¹³C₂, 98%) glycine (**SM-1**) (8.9 g, 114.4 mmol). The solid will be suspended in 245 mL of CH₂Cl₂. Diisopropylethylamine (65.6 mL, 377.5 mmol) will be added with stirring. Chlorotrimethylsilane (65.6 mL, 514.8 mmol) will then be added slowly, and the solution refluxed for 1.5 hours. The flask will be transferred to an ice bath, and benzyl chloroformate (Cbz-Cl, 15.6 mL, 108.7 mmol) is added in one portion via syringe. The stirred solution will be allowed to warm to room temperature overnight. The reaction mixture will then be concentrated and added to 1 L of 2.5% aqueous NaHCO₃ and transferred to a separatory funnel. The solution will be washed with ether (3 x 200 mL). The ether washes will then be combined and back extracted with water (2 x 200 mL). The aqueous layers will be combined and acidified to pH 2 with 2M aqueous HCl. This solution will be extracted with EtOAc (4 x 250 mL). The EtOAc layers will be washed with brine (3 x 250 mL), dried over Na₂SO₄, and filtered. The solvent will be evaporated *in vacuo*, yielding the desired product **I-1** (expected yield 21.7 g, 102.6 mmol, 95%)

Intermediate 2 (I-2): N-Cbz-(1,2-¹³C₂, 98%)-glycine acid chloride

To 100 mL of toluene will be added 5.6 g (27 mmol) triply labeled carbobenzyloxyglycine (**I-1**) to form a suspension. To this suspension will be added dimethylformamide (1 mL) and then oxalyl chloride (2.7 mL, 30 mmol) drop wise at room temperature. After ten minutes the solution should become clear. At this point the toluene, excess oxalyl chloride and HCl will be removed under reduced pressure. The residual oil will be dissolved in dry toluene and the toluene will be removed under reduced pressure yielding the desired product **I-2** (expected yield 6.2 g, 27 mmol, quantitative). The acid chloride **I-2** will be used without further purification.

Intermediate 3 (I-3): (1,2-¹³C₂, 98%)-{[4-Chloro-2-(2-chloro-benzoyl)-phenylcarbamoyl]-methyl}-carbamic acid benzyl ester

To 8 mL of dry ether will be added 1.4 g (6.07 mmol) of the triply labeled Cbz-glycine acid chloride (**I-2**). To this solution will be added dropwise 1.65 g (6.2 mmol) of (2-amino-5-chlorophenyl)(2-chlorophenyl)methanone (**SM-2**) dissolved in 30 mL of dry ether over 40 min. A

crystal slurry should form and it will be stirred for another two hours. The pH will be adjusted to 11 by slow addition of 5N NaOH and the solution will be stirred for another two hours. The ether layer will be separated and washed with water several times followed by several washes with 1M HCl. The organic extracts will be dried over anhydrous Na₂SO₄. The filtered solution will be evaporated *in vacuo*. The residue will be crystallized in 100 mL ethanol to produce **I-3** (expected yield 2.4 g, 5.3 mmol, 85%).

Intermediate 4 (I-4): (1,2-¹³C₂, 98%)-2-Amino-N-[4-chloro-2-(2-chloro-benzoyl)-phenyl]-acetamide

A solution of 1.5 g (3.26 mmol) of **I-3** and 8 mL of 30% HBr in acetic acid will be stirred for 1 hour at room temperature. After 1 hour 100 mL of dry ether will be added and the mixture will be stirred for five minutes. The ether solution will be decanted and the precipitate will be washed with 50 mL of dry ether. The solid will be suspended in 25 mL of ether, chilled in an ice bath and 8 mL of 10% NaOH will be added. This mixture will be stirred and the ether will then be separated, washed with water and evaporated under reduced pressure to yield **I-4** (expected yield 1.06 g, 3.26 mmol, quantitative yield). The product **I-4** will be used without further purification.

Intermediate 5 (I-5): (1,2-¹³C₂, 98%)-7-Chloro-5-(2-chloro-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one

To 25 mL freshly distilled pyridine will be added 1.06 g (3.26 mmol) **I-4**. The solution will be refluxed under nitrogen atmosphere for 16 hr. The pyridine will be evaporated under reduced pressure and the residue purified by preparative HPLC (mobile phase: MeOH:H₂O, 80:20, flow rate: 10 mL/min) fractions containing **I-5** will be combined, evaporated and crystallized in ethanol (expected yield 1g, 3.26 mmol, quantitative yield).

Intermediate 6 (I-6): (1,2-¹³C₂, 98%)-7-Chloro-5-(2-chloro-phenyl)-4-oxy-1,3-dihydro-benzo[e][1,4]diazepin-2-one

A solution of 1 g (3.26 mmol) of **I-5** in 50 mL of CH₂Cl₂ will be added dropwise to a stirred solution of 0.83 g (4.8 mmol) *m*-chloroperoxybenzoic acid (previously washed with a pH 7.4 buffer solution and dried *in vacuo*) in 10 mL of CH₂Cl₂ at 20 to 25°C. The solution will be stirred for 10 hours at room temperature and then another 0.83 g (4.8 mmol) *m*-chloroperoxybenzoic will be added. After another 10 hours of constant stirring the reaction mixture will be brought to pH 8.0 with 25% ammonium hydroxide and washed thoroughly with water. The solid white precipitate will be filtered and dried *in vacuo*. The combined solids will be crystallized from 7 mL of ethanol to produce the product **I-6** (expected yield 0.8 g, 2.47 mmol, 75%).

Intermediate 7 (I-7): (1,2-¹³C₂, 98%)-Acetic acid 7-chloro-5-(2-chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl ester

A suspension of 1.0 g (3.1 mmol) of **I-6** in 10 mL of acetic anhydride will be stirred and heated on a water bath for three hours at 60-70°C. Once the solution clears it will be evaporated *in*

vacuo and the residue will be dissolved in 5 mL of ethanol and crystallized to produce the product **I-7** (expected yield 1.0 g, 2.75 mmol, 88%).

(1,2-¹³C₂, 98%)-Lorazepam

One gram of **I-7** (2.75 mmol) will be dissolved in 10 mL of methanol and then 6 mL of 4N NaOH will be added. After 30 min, a solid precipitate is expected that will dissolve on the addition of 50 mL water. The solution will be acidified with acetic acid and extracted with CH₂Cl₂. After separation, the CH₂Cl₂ will be washed three times with 20 mL of water, dried on Na₂SO₄ and evaporated *in vacuo*. The solid will be purified on preparative HPLC (mobile phase: MeOH:H₂O, 30:70, flow rate: 10 mL/min). Fractions containing **1** will be combined, evaporated and crystallized in 2 mL ethanol to produce pure **1** (0.47 g, 1.46 mmol, 53%).

EXAMPLE 2: SYNTHESIS OF (1,2-¹³C₂-3-¹⁵N, 98%) LORAZEPAM

The synthesis of triple isotope labeled lorazepam was carried out using a modification of the protocol set forth in Koves, G.J. (*Journal of Radiolabeled Compounds and Radiopharmaceuticals* (1991) 29(1) 15-22) and is described in **Figure 2**. The synthesis is a modification of the protocol set forth in Example 1 with the only difference in the synthetic details being the use of (U-¹³C₂, 98%, ¹⁵N, 98%) glycine (**SM-3**) as the amino acid precursor.

EXAMPLE 3: SYNTHESIS OF (1,2-¹³C₂-3-¹⁵N, 98%) OXAZEPAM

The synthesis of triple isotope labeled oxazepam was carried out using a modification of the protocol set forth in Koves, G.J. (*Journal of Radiolabeled Compounds and Radiopharmaceuticals* (1991) 29(1) 15-22) and is described in **Figure 3**. The synthesis is a modification of the protocol set forth in Example 1 with the only difference in the synthetic details being the use of (U-¹³C₂, 98%, ¹⁵N, 98%) glycine (**SM-3**) as the amino acid precursor and (2-amino-5-chloro)-benzophenone as the benzophenone precursor (**SM-5**).

EXAMPLE 4: SYNTHESIS OF (1,2-¹³C₂-3-¹⁵N, 98%) CLONAZEPAM

The synthesis of triple isotope labeled clonazepam was carried out using a modification of the protocol set forth in Koves, G.J. (*Journal of Radiolabeled Compounds and Radiopharmaceuticals* (1991) 29(1) 15-22) and Sternbach, L.H. *et al.* (*Journal of Medicinal Chemistry*, (1963) 6, 261-265) and is described in **Figure 4**. The synthesis is a modification of the protocol set forth in Example 1 with the only difference in the synthetic details being the use of (U-¹³C₂, 98%, ¹⁵N, 98%) glycine (**SM-3**) as the amino acid precursor and (2-amino-5-chloro)-benzophenone as the benzophenone precursor (**SM-6**). Additionally, Clonazepam synthesis is complete upon cyclization to form the diazepine ring system (i.e., conversion of **I-26** to **4**).

EXAMPLE 5: SYNTHESIS OF $^{13}\text{C}_6$ -(2*R*, 2'*R*)-(+)-THREOMETHYLPHENIDATE HYDROCHLORIDE

The synthesis of isotope labeled methylphenidate was carried out using a modification of the protocol set forth in Thai et al. (*J. Med. Chem.* (1998), **41**, 591-601) and is described in **Figure 5** and the following written description.

Intermediate 27 (I-27):

Under a nitrogen atmosphere, a solution of $^{13}\text{C}_6$ -bromobenzene (**SM-7**) (37.98 mmol) in THF (25 mL) is to be cooled to -78°C . To this mixture is added *s*-BuLi (32.1 mL, 41.78 mmol, 1.3 M in cyclohexane) over 20 min with the temperature maintained at less than -50°C . The reaction mixture is aged for 15 min at -78° . The solvent is removed under reduced pressure and the residue is then redissolved in 20 mL hexanes to produce a 2 M solution of I-27.

Intermediate 28 (I-28):

A solution of hydroxamate **SM-8** (400 mg, 1.47 mmol) in Et₂O (6.3 mL) is brought to -23°C under an inert atmosphere, and a 2.0 M solution of $^{13}\text{C}_6$ phenyl lithium **I-27** in hexanes (735 microliters, 1.47 mmol) is added dropwise via syringe over 15 min. Stirring is continued at -23°C for 3 h, after which the reaction mixture is poured into an ice-chilled 1 M KH₂PO₄ solution (20 mL). The aqueous layer is extracted with EtOAc (4 x 15 mL), and the combined EtOAc layer is dried, filtered, and evaporated. Chromatography over silica gel eluting with 7.5-20% EtOAc in hexanes gives 200 mg of ketone **I-28** (47% yield) as well as 143 mg of recovered starting material SM-8. Synthesis of SM-8 and the above conditions are described in: Thai and co-workers, *J. Med. Chem.* (1998) **41**, 591-601.

Intermediate 29 (I-29):

To a suspension of methyltriphenylphosphonium bromide (230 mg, 0.644 mmol) in THF (1.0 mL) is added solid potassium tert-butoxide (72.2 mg, 0.644 mmol), and the resulting yellow suspension is allowed to stir for 10 min. A solution of **I-28** (124 mg, 0.429 mmol) in THF (2.0 mL) is then added dropwise via syringe and the reaction allowed to proceed for 5 min. The reaction is quenched with water (1.0 mL) and suspended between EtOAc (15 mL) and water (15 mL). The aqueous layer is extracted with EtOAc (2 x 15 mL). The combined EtOAc layers are dried, filtered, and evaporated to an oil which is then filtered through a plug of silica gel eluting with 9% EtOAc in hexanes to give 115 mg (93%) of **I-29** as a colorless oil. See Thai and co-workers, *J. Med. Chem.* (1998) **41**, 591-601.

Intermediate 30 (I-30):

To a solution of I-29 (115 mg, 0.4 mmol) in THF (2.0 mL) is added 1.0 M BH₃.THF (800 microliters, 0.8 mmol) dropwise at room temperature via syringe over about 5 min. The reaction mixture is then stirred for 4 h after which water (1.0 mL), 3 N NaOH (1.0 mL), and 30% H₂O₂ (2.0 mL) are added consecutively. Stirring is continued overnight. The resulting mixture is

suspended between EtOAc (20 mL) and water (15 mL), and the aqueous layer is extracted with EtOAc (3 x 10 mL). The combined EtOAc layers were dried, filtered, and evaporated to an oil which is purified by silica gel chromatography eluting with 16-20% EtOAc in hexanes. The less polar (1R, 2R) -**I-30** is obtained as a white solid (78 mg, 64% yield). See Thai and co-workers, *J. Med. Chem.* (1998) **41**, 591-601.

Intermediate 31 (I-31):

Alcohol **I-30** (228 mg, 0.748 mmol) is dissolved in DMF (3.0 mL), and PDC (984 mg, 2.62 mmol) is added. After 17 h of stirring, the reaction is quenched with water (40 mL) and the resulting mixture extracted with Et₂O (6 x 20 mL). Combined Et₂O layers are then extracted with 0.5 N NaOH (4 x 30 mL) and the alkaline solution brought to pH=2.0 with 3 N HCl. A white precipitate is formed and is extracted into EtOAc (4 x 30 mL) which is dried, filtered, and evaporated under reduced pressure to give a crude colorless oil containing the carboxylic acid **I-31** (194 mg). See Thai and co-workers, *J. Med. Chem.* (1998) **41**, 591-601.

¹³C₆-(2R,2'R)-(+)-threomethylphenidate 5

A portion (180 mg) of the crude oil **I-31** is treated with excess diazomethane in ether (10 mL). The solution is evaporated to a light yellow oil which is stirred in 3 N methanolic HCl (10 mL) at room temperature overnight. Evaporation under reduced pressure provides a crude off-white solid which is recrystallized from EtOH/Et₂O to give 125 mg of (2R,2'R)-**5** as a white solid (67% yield from (1R,2R)-**I-30**).

EXAMPLE 6: SYNTHESIS OF DEUTERIUM LABELED CODEINE

This example shows the synthesis of deuterium (D) labeled codeine from Thebaine, a natural opioid that is produced in high quantities by some varieties of *Papaver somniferum* (Blakemore PR, White JD, Chem Comm. 2002: 1159-1168). See **Figure 6**.

D₁-Codeinone O-2.

A stirred solution of 100 g Thebain **O-1** in CH₂Cl₂ (1L) is cooled to below 3°C in an ice-salt bath and then rapidly saturated with anhydrous DBr with continued cooling. The temperature is kept below 15°C by controlling the rate of DBr addition. The DBr is added until the solution is saturated (~35 min), as indicated by a drop in temperature. The mixture is then cooled below 5°C and poured into cold, stirred saturated NaHCO₃ solution (2 L). The neutral mixture is adjusted to pH 12 by the addition of 50% NaOH solution. The organic layer is separated and the aqueous phase washed twice with CH₂Cl₂ (400 mL). The organic phases are combined, dried over anhydrous Na₂SO₄ and the solvent is removed in vacuo to leave a semicrystalline brown residue. The residue is triturated with MeOH (100 mL) and chilled. The crystals are collected and washed with three portions of cold MeOH (20 mL). These crystals are suspended in H₂O and, with warming and

stirring, the mixture is adjusted to pH 1-2 by the addition of concentrated HCl. The clear yellow solution is cooled in ice to 30°C, and 50% NaOH is added to give a thick suspension (pH approx. 14). The suspension is cooled below 15°C, and the crystals are collected, pressed dry, and then washed with cold water. The crystals should be dried overnight under high vacuum at 65°C to give 64.5 g (67%) of O-2.

See Kotick M. P.; Leland, D.L, Polazzi, J.O.; Schut, R.N. J. Med. Chem. (1980) 23, 166-174.

D₂-Codeine (O-3).

To a solution of 194 mg of D1-codeinone O-2 in 10 ml methanol is added 0.5 g sodium borodeuteride (NaBD₄) which has been suspended in 12 ml methanol. The mixture is allowed to stand for 1.5 hours, concentrated to 10 ml in vacuo and diluted with 10 ml of 10% sodium hydroxide. The clear colorless solution is heated momentarily to boiling, diluted with water and extracted four times with chloroform. The washed, dried and filtered chloroform extract is then recrystallized from dilute methanol to give an expected yield of 173 mg D2-Codeine (O-3).

See Gates, M. J. *Am. Chem. Soc.* (1953) 17, 4340-4341.

D₁-Codeine (O-4).

To a solution of 194 mg of D1-codeinone O-2 in 10 ml methanol is added 0.5 g sodium borohydride which has been suspended in 12 ml methanol. The mixture is allowed to stand for 1.5 hours, concentrated to 10 ml in vacuo and diluted with 10 ml of 10% sodium hydroxide. The clear colorless solution is heated momentarily to boiling, diluted with water and extracted four times with chloroform. The washed, dried and filtered chloroform extract is then recrystallized from dilute methanol to give an expected yield of 173 mg D1-Codeine (O-4).

See Gates, M. J. *Am. Chem. Soc.* (1953) 17, 4340-4341.

EXAMPLE 7: SYNTHESIS OF DEUTERIUM AND ¹⁸O LABELED OXYCODONE

This example describes the synthesis of deuterium and ¹⁸O labeled oxycodone. See Figure 7.

Hydroxycodeinone (O-5)

Hydrogen peroxide (30%, 1.3 mL, 13 mmol) is added to a solution of thebaine O-1 (3.11 g, 10 mmol) in a mixture of formic acid (88%, 1.3 mL) and H₂SO₄ (0.7%, 4.1 mL). The mixture is heated at 40°C (bath temperature) for 6.5 h, cooled, diluted with water (10 mL), and made basic with concentrated NH₄OH. The precipitate is filtered, washed with H₂O and dried (MgSO₄). The product is recrystallized from EtOH-CHCl₃ to yield O-5 (2.70 g, expected yield 86%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

(D₂)-oxycodone (O-6)

To a solution of O-5 (2.00 g, 6.38 mmol) in deuterioacetic acid (CH_3COOD) (10% in D_2O , 40 mL) is added $[\text{Pd-BaSO}_4$ (5%, 1.00g)]. The catalyst is then filtered and washed with H_2O and the filtrate is made basic with concentrated NH_4OH . The solution is saturated with NaCl and extracted with CHCl_3 . The extracts are washed with saturated NaCl solution and dried (MgSO_4), and the solvent is removed. The resulting crystalline solid is then washed with Et_2O and dried. Expected yield of O-6 is 1.91 g (95%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

($^{18}\text{O}_1$)-hydroxycodone (O-7)

Thebaine O-1 (35 mg, 0.11 mmol) is combined with *meso*-tetraphenylporphyrin (5,10,15,20-tetraphenyl-21H, 23H-porphyrine; TPP) (5 mg, 0.03 mmol) in 50 mL of CH_2Cl_2 . The solution is then acidified with trifluoroacetic acid to $\text{pH}=4$. ^{18}O oxygen ($^{18}\text{O}_2$) is circulated through the solution in a round-bottomed flask fitted with a cooling water-jacket [Currently >95% pure $^{18}\text{O}_2$ is available from Cambridge Isotope Laboratories]. The mixture is irradiated from a distance of 45 cm with an Osram Ultra-Vitalux sun lamp (300W) for 55 min. The mixture is concentrated to 20 mL under reduced pressure and then 50 mL of ethyl ether is added. The resulting precipitate is decanted and washed with ethyl ether, affording an expected 25 mg of the trifluoroacetate salt of O-7 (61% yield). See Lopez, D.; Quinoa, E.; Riguera, R.; J. Org. Chem. (2000) 65(15) 4671-4678.

(D_2 , $^{18}\text{O}_1$)-oxycodone (O-8)

To a solution of O-7 (2.00 g, 6.38 mmol) in deuterioacetic acid (CH_3COOD) (10% in D_2O , 40 mL) is added $[\text{Pd-BaSO}_4$ (5%, 1.00g)]. The solution is then placed under deuterium (D_2) gas atmosphere until the reaction is complete. The catalyst is then filtered and washed with H_2O and the filtrate is made basic with concentrated NH_4OH . The solution is saturated with NaCl and extracted with CHCl_3 . The extracts are washed with saturated NaCl solution and dried (MgSO_4), and the solvent is removed. The resulting crystalline solid then washed with Et_2O and dried. Expected yield of O-8 is 1.91 g (95%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

($^{18}\text{O}_1$)-oxycodone (O-9)

To a solution of O-7 (2.00 g, 6.38 mmol) in acetic acid (CH_3COOH) (10% in H_2O , 40 mL) is added $[\text{Pd-BaSO}_4$ (5%, 1.00g)]. The solution is then placed under hydrogen gas atmosphere (H_2) until the reaction is complete. The catalyst is then filtered and washed with H_2O and the filtrate is made basic with concentrated NH_4OH . The solution is saturated with NaCl and extracted with CHCl_3 . The extracts are washed with saturated NaCl solution and dried (MgSO_4), and the solvent is removed. The resulting crystalline solid O-9 is then washed with Et_2O and dried. Expected yield of O-9 is 1.91 g (95%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

EXAMPLE 8: SYNTHESIS OF DEUTERIUM LABELED HYDROCODONE

This example describes the synthesis of deuterium labeled hydrocodone. See **Figure 8**.

(D₃)-hydrocodone (O-10)

To a solution of O-2 (2.00 g, 6.4 mmol) in deuterioacetic acid (CH₃COOD) (10% in D₂O, 40 mL) is added [Pd-BaSO₄ (5%, 1.00g)]. The solution is then placed under deuterium (D₂) gas atmosphere until the reaction is complete. The catalyst is then filtered and washed with H₂O and the filtrate is made basic with concentrated NH₄OH. The solution is saturated with NaCl and extracted with CHCl₃. The extracts are washed with saturated NaCl solution and dried (MgSO₄), and the solvent is removed. The resulting crystalline solid O-10 is then washed with Et₂O and dried. Expected yield of O-10 is 1.9 g (95%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

(D₂)-hydrocodone (O-12)

To a solution of Codeinone O-11 (2.00 g, 6.4 mmol) in deuterioacetic acid (CH₃COOD) (10% in D₂O, 40 mL) is added [Pd-BaSO₄ (5%, 1.00g)]. The solution is then placed under deuterium (D₂) gas atmosphere until the reaction is complete. The catalyst is then filtered and washed with H₂O and the filtrate is made basic with concentrated NH₄OH. The solution is saturated with NaCl and extracted with CHCl₃. The extracts are washed with saturated NaCl solution and dried (MgSO₄), and the solvent is removed. The resulting crystalline solid O-12 is then washed with Et₂O and dried. Expected yield of O-12 is 1.9 g (95%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

(D₁)-hydrocodone (O-13)

To a solution of (D₁)-Codeinone O-2 (2.00 g, 6.4 mmol) in acetic acid (CH₃COOH) (10% in H₂O, 40 mL) is added [Pd-BaSO₄ (5%, 1.00g)]. The solution is then placed under hydrogen (H₂) gas atmosphere until the reaction is complete. The catalyst is then filtered and washed with H₂O and the filtrate is made basic with concentrated NH₄OH. The solution is saturated with NaCl and extracted with CHCl₃. The extracts are washed with saturated NaCl solution and dried (MgSO₄), and the solvent is removed. The resulting crystalline solid O-13 is then washed with Et₂O and dried. Expected yield of O-13 is 1.9 g (95%). See Iijima, I.; Minamikawa, J.; Jacobson, A.E.; Brossi, A.; Rice, K.C.; J. Med. Chem. (1978) 21, 398.

EXAMPLE 9: SYNTHESIS OF ¹³C, ¹⁵N LABELED DEXTROAMPHETAMINE

This example describes the synthesis of ¹³C, ¹⁵N labeled dextroamphetamine. See **Figure 9**.

Intermediate a-2 (¹³C methyl magnesium bromide):

¹³CH₃Br (**a-1**, 1.1 g, 11.7 mmol) is to be condensed into a 25 mL vacuum-line bulb. A dry ice/acetone condenser and a 100 mL Schlenk flask containing Reade high-purity magnesium

turnings (218 mg, 8.97 mmol) are connected directly to a high-vacuum line through the side arm near the base of the condenser. The apparatus is then evacuated and diethyl ether (~25 mL) is transferred into the reaction flask and freeze-pump-thaw degassed. Before the final thawing the condenser is charged with dry ice/acetone and an aliquot of $^{13}\text{CH}_3\text{Br}$ is condensed into the reaction flask. The reaction mixture is allowed to warm slowly to room temperature; stirring is to be started after bubbling shows that the reaction has been initiated. The rest of the $^{13}\text{CH}_3\text{Br}$ is added in aliquots (using a mercury manometer to control the addition) at a rate that maintains gentle reflux of the solution without external heating. After the addition is complete, the reaction is stirred until all of the magnesium is consumed (~1 h). The diethyl ether and excess $^{13}\text{CH}_3\text{Br}$ is removed under reduced pressure to yield a white crystalline product **a-2**, which is dried under vacuum for 1 h. The product is extracted with diethyl ether (35 mL) and filtered through a glass frit to give a clear, colorless solution (~0.36 M), which is used without further purification. See Bullock R.M. and co-workers, *J. Am. Chem. Soc.* (1989), **111**, 3897-3908.

Intermediate a-5 (^{15}N -*R*-*tert*-butanesulfinamide):

A 5 L three-necked round bottomed flask equipped with a mechanical stirrer, an ammonia condenser, and a nitrogen inlet is charged with 2 L of liquid ^{15}N -ammonia. A few crystals of $\text{Fe}(\text{NO}_3)_3$ are added and lithium wire (13.3 g, 1.92 mol) is added in ca. 500 mg portions. A -78C bath is periodically raised to the bottom of the flask to abate any refluxing caused by the formation of $\text{Li}^{15}\text{NH}_2$. As lithium is added, the mixture will become blue, but fade to reveal a gray suspension. When all the lithium wire is added and the mixture has become gray, the flask is submerged into the -78C bath. After 30 min a solution of thiosulfinate **a-3** (92.9 g, 0.479 mol) in 500 mL of THF is slowly added over the course of an hour. Once the addition is complete the mixture is stirred an additional 15 min before 128 g (2.40 mol) of NH_4Cl is added slowly and carefully. The cold bath is removed and stirring continued until the mixture reaches ambient temperature. The remaining volatile material is removed under aspirator pressure. To the remaining residue is added 250 mL of water with swirling to dissolve all the salts. The resulting mixture is extracted with 1.5 L of EtOAc (3 x) and the organic layers washed once each with the same 150 mL of brine before they are combined and dried (Na_2SO_4). The solid remaining after removal of solvent is recrystallized once from hexanes to provide an expected yield of 45.6 g (79%) of enantiomerically pure ^{15}N -*R*-*tert*-butanesulfinamide **a-5**. The synthesis of thiosulfinate **a-3** and reaction with lithium amide is described in Liu, G. Cogan, D.A., Ellman, J.A. *J. Am. Chem. Soc.* (1997), **119**, 9913-9914.

Intermediate a-7 (^{15}N -2-Methyl-propane-2-sulfinic acid [2-phenyl-eth-(E)-ylidene]-amide):

To a solution of ^{15}N -*tert*-butanesulfinamide **a-5** (0.12 g, 1.0 mmol) and phenyl-acetaldehyde **a-6** (1.2 mmol) in CH_2Cl_2 (2.5 mL) is added titanium tetraethoxide (purity: 85-95%, 0.46 mL, 2 mmol) under a nitrogen atmosphere. The mixture is stirred at room temperature for 15

h. Diatomaceous earth (8 mL) is placed in a polypropylene SPE cartridge (12 mL, with 70 micrometer PE frit) equipped with a PTFE stopcock and then is soaked with water (2.5 mL). The reaction mixture is then to be transferred to the SPE cartridge while rinsing with 5 mL of CH₂Cl₂, and the cartridge is plugged with a glass stopper coated with PTFE seal tape. The cartridge is shaken vigorously for 30 s so that the diatomaceous earth flows freely in the cartridge. The mixture is shaken for 30 min with a wrist action shaker. During the mixing, the cartridge is shaken vigorously with hands at intervals to ensure effective mixing. The solid phase is filtered and washed with CH₂Cl₂ until no product can be found in the elution. The filtrate is evaporated and filtered through a 0.5-cm plug of silica gel (Merck 60 230-400 mesh) in a glass pipet. The silica gel is washed with a small amount of a 9:1 CH₂Cl₂/Et₂O mixture. The product imine **a-7** (1.0 mmol) contaminated with excess aldehyde will be obtained by evaporation of the solvent from the filtrate. See Mukade, T. Dragoli, D.R. Ellman, J.A., *J. Comb. Chem.* (2003), 5, 590-596.

Intermediate a-8 (¹³C-¹⁵N-2-Methyl-propane-2-sulfinic acid ((S)-1-methyl-2-phenyl-ethyl)-amide):

The mixture containing 1 mmol of imine **a-7** is dissolved in CH₂Cl₂ (5 mL) and cooled to -48°C. To this cooled mixture, ¹³CH₃MgBr **a-2** in diethyl ether (3.0 M, 0.800 mL, 2.40 mmol) is added slowly dropwise. The reaction mixture is stirred at -48°C for 6 h and then is allowed to gradually warm to room temperature. After stirring overnight, the reaction is quenched by the addition of saturated aqueous ammonium chloride solution (2 mL). After stirring vigorously for 10 min, the mixture is transferred to a 1PS filter cartridge equipped with a PTFE stopcock, and the organic phase is isolated. The aqueous phase is rinsed with dichloromethane (3 x 2 mL) and evaporated to afford the desired crude sulfonamide product **a-8** (expected yield 77% with 91% ee). The product **a-8** is used without further purification. See Mukade, T. Dragoli, D.R. Ellman, J.A., *J. Comb. Chem.* (2003), 5, 590-596.

Intermediate a-9 (¹³C, ¹⁵N-dextroamphetamine)

The product **a-8** (0.77 mmol) is dissolved in methanol (2 mL). To this mixture is added 4 N hydrogen chloride in 1,4-dioxane (2 mL). The mixture is stirred for 30 min and then concentrated to dryness. The obtained mixture is distributed in 0.5 N hydrochloric acid (2 mL) and dichloromethane (2 mL) and is then transferred to a 1PS filter cartridge (12 mL) equipped with a PTFE stopcock. The organic layer is removed, and the aqueous layer is washed with CH₂Cl₂ (3 x 2 mL). A 2 N sodium hydroxide solution (2 mL) is then added to the aqueous layer, and the resulting free amine was extracted with dichloromethane (3 x 2 mL). The solvent is then removed under reduced pressure to obtain **a-9**. See Mukade, T. Dragoli, D.R. Ellman, J.A., *J. Comb. Chem.* (2003), 5, 590-596.

EXAMPLE 10: SYNTHESIS OF ¹³C, ¹⁵N LABELED LEVAMPHETAMINE

This example describes the synthesis of ^{13}C , ^{15}N labeled levamphetamine. See Figure 10.

Intermediate a-11 (^{15}N -*S*-*tert*-butanesulfinamide):

A 5 L three-necked round bottomed flask equipped with a mechanical stirrer, an ammonia condenser, and a nitrogen inlet is charged with 2 L of liquid ^{15}N -ammonia. A few crystals of $\text{Fe}(\text{NO}_3)_3$ are added and lithium wire (13.3 g, 1.92 mol) is added in ca. 500 mg portions. A -78°C bath is periodically raised to the bottom of the flask to abate any refluxing caused by the formation of $\text{Li}^{15}\text{NH}_2$. As lithium is added, the mixture will become blue, but fade to reveal a gray suspension. When all the lithium wire is added and the mixture has become gray, the flask is submerged into the -78°C bath. After 30 min a solution of thiosulfinate **a-10** (92.9 g, 0.479 mol) in 500 mL of THF is slowly added over the course of an hour. Once the addition is complete the mixture is stirred an additional 15 min before 128 g (2.40 mol) of NH_4Cl is added slowly and carefully. The cold bath is removed and stirring continued until the mixture reaches ambient temperature. The remaining volatile material is removed under aspirator pressure. To the remaining residue is added 250 mL of water with swirling to dissolve all the salts. The resulting mixture is extracted with 1.5 L of EtOAc (3 x) and the organic layers washed once each with the same 150 mL of brine before they are combined and dried (Na_2SO_4). The solid remaining after removal of solvent is recrystallized once from hexanes to provide an expected yield of 45.6 g (79%) of enantiomerically pure ^{15}N -*S*-*tert*-butanesulfinamide **a-11**. The synthesis of thiosulfinate **a-10** and reaction with lithium amide is described in Liu, G. Cogan, D.A., Ellman, J.A. *J. Am. Chem. Soc.* (1997), **119**, 9913-9914.

Intermediate a-12 (^{15}N -2-Methyl-propane-2-sulfinic acid [2-phenyl-eth-(E)-ylidene]-amide):

To a solution of ^{15}N -*tert*-butanesulfinamide **a-11** (0.12 g, 1.0 mmol) and phenyl-acetaldehyde **a-6** (1.2 mmol) in CH_2Cl_2 (2.5 mL) is added titanium tetraethoxide (purity: 85-95%, 0.46 mL, 2 mmol) under a nitrogen atmosphere. The mixture is stirred at room temperature for 15 h. Diatomaceous earth (8 mL) is placed in a polypropylene SPE cartridge (12 mL, with 70 micrometer PE frit) equipped with a PTFE stopcock and then is soaked with water (2.5 mL). The reaction mixture is then to be transferred to the SPE cartridge while rinsing with 5 mL of CH_2Cl_2 , and the cartridge is plugged with a glass stopper coated with PTFE seal tape. The cartridge is shaken vigorously for 30 s so that the diatomaceous earth flows freely in the cartridge. The mixture is shaken for 30 min with a wrist action shaker. During the mixing, the cartridge is shaken vigorously with hands at intervals to ensure effective mixing. The solid phase is filtered and washed with CH_2Cl_2 until no product can be found in the elution. The filtrate is evaporated and filtered through a 0.5-cm plug of silica gel (Merck 60 230-400 mesh) in a glass pipet. The silica gel is washed with a small amount of a 9:1 $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$ mixture. The product imine **a-12** (1.0 mmol) contaminated with excess aldehyde will be obtained by evaporation of the solvent from the filtrate. See Mukade, T. Dragoli, D.R. Ellman, J.A., *J. Comb. Chem.* (2003), **5**, 590-596.





Intermediate a-13 (^{13}C - ^{15}N -2-Methyl-propane-2-sulfinic acid ((S)-1-methyl-2-phenyl-ethyl)-amide):

The mixture containing 1 mmol of imine **a-12** is dissolved in CH_2Cl_2 (5 mL) and cooled to -48°C . To this cooled mixture, $^{13}\text{CH}_3\text{MgBr}$ **a-2** in diethyl ether (3.0 M, 0.800 mL, 2.40 mmol) is added slowly dropwise. The reaction mixture is stirred at -48°C for 6 h and then is allowed to gradually warm to room temperature. After stirring overnight, the reaction is quenched by the addition of saturated aqueous ammonium chloride solution (2 mL). After stirring vigorously for 10 min, the mixture is transferred to a 1PS filter cartridge equipped with a PTFE stopcock, and the organic phase is isolated. The aqueous phase is rinsed with dichloromethane (3 x 2 mL) and evaporated to afford the desired crude sulfonamide product **a-13** (expected yield 77% with 91% ee). The product **a-13** is used without further purification. *See* Mukade, T. Dragoli, D.R. Ellman, J.A., J. Comb. Chem. (2003), 5, 590-596.

a-14 (^{13}C , ^{15}N -levamphetamine):

The product **a-13** (0.77 mmol) is dissolved in methanol (2 mL). To this mixture is added 4 N hydrogen chloride in 1,4-dioxane (2 mL). The mixture is stirred for 30 min and then concentrated to dryness. The obtained mixture is distributed in 0.5 N hydrochloric acid (2 mL) and dichloromethane (2 mL) and is then transferred to a 1PS filter cartridge (12 mL) equipped with a PTFE stopcock. The organic layer is removed, and the aqueous layer is washed with CH_2Cl_2 (3 x 2 mL). A 2 N sodium hydroxide solution (2 mL) is then added to the aqueous layer, and the resulting free amine was extracted with dichloromethane (3 x 2 mL). The solvent is then removed under reduced pressure to obtain **a-14**. *See* Mukade, T. Dragoli, D.R. Ellman, J.A., J. Comb. Chem. (2003), 5, 590-596.

EXAMPLES 11-14: SYNTHESIS OF MONO-LABELED AMPHETAMINES



EXAMPLE 11 (^{13}C -dextroamphetamine) **a-15**

Prepare as described above for **a-9** but use unlabeled NH_3 rather than $^{15}\text{NH}_3$.

EXAMPLE 12 (^{13}C -levamphetamine) **a-16**

Prepare as described above for **a-14** but use unlabeled NH_3 rather than $^{15}\text{NH}_3$.

EXAMPLE 13 (¹⁵N-dextroamphetamine) a-17

Prepare as described above for **a-9** but use unlabeled CH₃Br rather than ¹³CH₃Br.

EXAMPLE 14 (¹⁵N-levamphetamine) a-18

Prepare as described above for **a-14** but use unlabeled CH₃Br rather than ¹³CH₃Br.

EXAMPLE 15 ¹³C, ¹⁵N-Benzedrine

Combine 1 equivalent **a-9** and 1 equivalent **a-14** with 1 equivalent H₂SO₄.

EXAMPLE 16 ¹³C, ¹⁵N-Actemin

Combine 1 equivalent **a-9** and 1 equivalent **a-14** with 2 equivalents H₃PO₄.

EXAMPLE 17 ¹³C, ¹⁵N-Dexamin (also called Dexedrine, Dextrostat)

Combine 1 equivalent **a-9** and 1 equivalent of H₂SO₄.

EXAMPLE 18 ¹³C, ¹⁵N-Tanphetamin (also called Synatan)

Combine 1 equivalent **a-9** and 1 equivalent of Tannic acid.

EXAMPLE 19 ¹³C-Benzedrine

Combine 1 equivalent **a-15** and 1 equivalent **a-16** with 1 equivalent H₂SO₄.

EXAMPLE 20 ¹³C-Actemin

Combine 1 equivalent **a-15** and 1 equivalent **a-16** with 2 equivalents H₃PO₄.

EXAMPLE 21 ¹³C-Dexamin (also called Dexedrine, Dextrostat)

Combine 1 equivalent **a-15** and 1 equivalent of H₂SO₄.

EXAMPLE 22 ¹³C -Tanphetamin (also called Synatan)

Combine 1 equivalent **a-15** and 1 equivalent of Tannic acid.

EXAMPLE 23 ¹⁵N-Benzedrine

Combine 1 equivalent **a-17** and 1 equivalent **a-18** with 1 equivalent H₂SO₄.

EXAMPLE 24 ¹⁵N-Actemin

Combine 1 equivalent **a-17** and 1 equivalent **a-18** with 2 equivalents H₃PO₄.

EXAMPLE 25 ¹⁵N-Dexamin (also called Dexedrine, Dextrostat)

Combine 1 equivalent **a-17** and 1 equivalent of H₂SO₄.

EXAMPLE 26 ¹⁵N -Tanphetamin (also called Synatan)

Combine 1 equivalent **a-17** and 1 equivalent of Tannic acid.

EXAMPLES 27-29: SYNTHESIS OF LABELED METHAMPHETAMINE**EXAMPLE 27 (¹³C, ¹⁵N-methamphetamine) a-19**

This example describes the synthesis of ¹³C, ¹⁵N-methamphetamine. See **Figure 11(a)**.

The amphetamine **a-9** (10 mmol) is combined with 3.33 mmol para-formaldehyde in 50 mL dry benzene. The mixture is placed in a round bottom flask affixed with a Dean-Stark trap. The

mixture is refluxed for two hours with continuous removal of water. The benzene is then removed using reduced pressure. To the residue is added 50 mL dry Et₂O and an excess of LiAlH₄ is slowly added. The mixture is stirred for one hour at room temperature. The reaction is quenched slowly with water, and extracted with CH₂Cl₂. The organic layer is dried using anhydrous MgSO₄ and evaporated to produce labeled methamphetamine **a-19**. See Bartoli and co-workers, *J. Med. Chem.* (1998), **41**, 1855-1868; Konosu and coworkers, *Chem. Pharm. Bull.* (1991), **39**, 2581-2589.

EXAMPLE 28 (¹³C-methamphetamine) **a-20**

This example describes the synthesis of ¹³C-methamphetamine. See Figure 11(b). Prepare as described above for **a-19** but start with **a-15**.

EXAMPLE 29 (¹⁵N-methamphetamine) **a-21**

This example describes the synthesis of ¹⁵N-methamphetamine. See Figure 11(c). Prepare as described above for **a-19** but start with **a-17**.

EXAMPLES 30-31: SYNTHESIS OF LABELED METHADONE

Intermediate **m-2**: ¹³C-ethylmagnesium bromide:

To 180 mmol magnesium in 30 mL dry diethyl ether is added dropwise 30 mL of a 6 M solution of ¹³C-ethylbromide **m-1** (180 mmol). The ethylbromide is added at a rate that maintains moderate boiling of the solvent. After 1-1.5 hr refluxing the resulting 3 M solution of ethylmagnesiumbromide **m-2** is used directly. See Novakov and co-workers *Chem. Res. Toxicol.* (2001), **14**, 1239-1246.

Intermediate **m-4**: D₃-ethylmagnesium bromide **m-4**:

To 180 mmol magnesium in 30 mL dry diethyl ether is added dropwise 30 mL of a 6 M solution of D₃-ethylbromide **m-3** (180 mmol). The ethylbromide is added at a rate that maintains moderate boiling of the solvent. After 1-1.5 hr refluxing the resulting 3 M solution of ethylmagnesiumbromide **m-4** is used directly. See Novakov and co-workers *Chem. Res. Toxicol.* (2001), **14**, 1239-1246.

EXAMPLE 30: ¹³C-*R*-(-)-methadone (**m-6**)

This example describes the synthesis of labeled methadone. See Figure 12.

All apparatus are dried and the reaction is carried out under an inert atmosphere of argon. A solution of (*R*)-(-)-2,2-diphenyl-4-dimethylaminopentanenitrile **m-5** (5.0 g, 0.018 mol) in toluene (15 mL) is added to a stirred solution of 3 M ¹³C-ethylmagnesium bromide **m-2** in ether (10.7 mL, 0.03 mol). The ether is removed under reduced pressure and the remaining solution is heated at reflux (135-140°C) for 3 h. The solution will go slightly cloudy. After cooling to room temperature

2N HCl (30 mL) is added with care and then stirring is continued at 135-140°C) for a further 30 min. The two phases are allowed to separate and cool to room temperature. After scratching the sides of the flask, a solid will start to crystallize from the aqueous phase. The flask should be cooled to complete crystallization and the white solid collected by filtration. This solid is then recrystallized from water to yield 2.7 g (43 %) of (*R*)-(-)-methadone hydrochloride **m-6**. See Hull and co-workers, *Tetrahedron: Asymmetry* (2003), **14**, 567-576 for a description of the synthesis of **m-5**.

EXAMPLE 31: D₃-*R*-(-)-methadone (m-7**)**

As described above for ¹³C-*R*-(-)-methadone **m-6** but substitute D₃-ethylmagnesium bromide **m-4** in place of ¹³C-ethylmagnesium bromide **m-2**. See Hull and co-workers, *Tetrahedron: Asymmetry* (2003), **14**, 567-576]

EXAMPLES 32-33: SYNTHESIS OF DEUTERATED MORPHINE

These examples describe the synthesis of deuterated morphine. See Figure 13.

EXAMPLE 32: D₂-Morphine (MO-3**)**

Double ²H labeled morphine can be prepared using a modification of the procedure described in Journal of Medicinal Chemistry, 1977, vol 20, 164-165. A solution of 2.99 g (10 mmol) of anhydrous D₂-Codiene **O-3** in 25 ml of CHCl₃ is to be added during 2 min to a well-stirred solution of 15 g (59.9 mmol) of BBr₃ in 175 ml of CHCl₃ maintained in the range 23-26 degrees C. A 10 ml portion of CHCl₃, which is added to rinse the addition funnel, is added to the reaction mixture and stirring is continued for 15 min at 23-26 degrees C. The reaction mixture which will consist of a suspension of white solid (in CHCl₃) is then poured into a well-stirred mixture of 80 g of ice and 20 ml of concentrated (28-30% NH₃) NH₄OH. The two-phase system is kept at -5 to 0 degrees C for 0.5 h (continuous stirring) and filtered. The resulting crystalline material is washed thoroughly with small portions of cold CHCl₃ and H₂O and dried to give 2.67 g (88.1 %) of slightly off-white **MO-3** monohydrate.

EXAMPLE 33: D₁-Morphine (MO-4**)**

Single ²H labeled morphine can be prepared using a modification of the procedure described in Journal of Medicinal Chemistry, 1977, vol 20, 164-165. A solution of 2.99 g (10 mmol) of anhydrous D₂-Codiene **O-3** in 25 ml of CHCl₃ is to be added during 2 min to a well-stirred solution of 15 g (59.9 mmol) of BBr₃ in 175 ml of CHCl₃ maintained in the range 23-26 degrees C. A 10 ml portion of CHCl₃, which is added to rinse the addition funnel, is added to the reaction mixture and stirring is continued for 15 min at 23-26 degrees C. The reaction mixture which will consist of a suspension of white solid (in CHCl₃) is then poured into a well-stirred mixture of 80 g

of ice and 20 ml of concentrated (28-30% NH_3) NH_4OH . The two-phase system is kept at -5 to 0 degrees C for 0.5 h (continuous stirring) and filtered. The resulting crystalline material is washed thoroughly with small portions of cold CHCl_3 and H_2O and dried to give 2.67 g (88.1%) of slightly off-white **MO-3** monohydrate.

EXAMPLES 34-36: SYNTHESIS OF DEUTERATED HYDROMORPHONE

These examples describe the synthesis of deuterated hydromorphone. See **Figure 14**.

EXAMPLE 34: D3-Hydromorphone (MO-10)

Triple ^2H labeled hydromorphone can be prepared using a modification of the procedure described in Journal of Medicinal Chemistry, 1977, vol 20, 164-165 and Tetrahedron Letters Vol. 25, 3335-3338, 1984. A solution of 2.99 g (10 mmol) of anhydrous D2-Hydrocodone **O-10** in 25 ml of CHCl_3 is to be added during 2 min to a well-stirred solution of 15 g (59.9 mmol) of BBr_3 in 175 ml of CHCl_3 maintained in the range 23-26 degrees C. A 10 ml portion of CHCl_3 , which is added to rinse the addition funnel, is added to the reaction mixture and stirring is continued for 15 min at 23-26 degrees C. The reaction mixture which will consist of a suspension of white solid (in CHCl_3) is then poured into a well-stirred mixture of 80 g of ice and 20 ml of concentrated (28-30% NH_3) NH_4OH . The two-phase system is kept at -5 to 0 degrees C for 0.5 h (continuous stirring) and filtered. The resulting crystalline material is washed thoroughly with small portions of cold CHCl_3 and H_2O and dried to give 2.67 g (88.1%) of slightly off-white **MO-10** monohydrate.

EXAMPLE 35: D2-Hydromorphone (MO-12)

Double ^2H labeled hydromorphone can be prepared using a modification of the procedure described in Journal of Medicinal Chemistry, 1977, vol 20, 164-165 and Tetrahedron Letters Vol. 25, 3335-3338, 1984. A solution of 2.99 g (10 mmol) of anhydrous D2-Hydrocodone **O-12** in 25 ml of CHCl_3 is to be added during 2 min to a well-stirred solution of 15 g (59.9 mmol) of BBr_3 in 175 ml of CHCl_3 maintained in the range 23-26 degrees C. A 10 ml portion of CHCl_3 , which is added to rinse the addition funnel, is added to the reaction mixture and stirring is continued for 15 min at 23-26 degrees C. The reaction mixture which will consist of a suspension of white solid (in CHCl_3) is then poured into a well-stirred mixture of 80 g of ice and 20 ml of concentrated (28-30% NH_3) NH_4OH . The two-phase system is kept at -5 to 0 degrees C for 0.5 h (continuous stirring) and filtered. The resulting crystalline material is washed thoroughly with small portions of cold CHCl_3 and H_2O and dried to give 2.67 g (88.1%) of slightly off-white **MO-12** monohydrate.

EXAMPLE 36: D1-Hydromorphone (MO-13)

Double ^2H labeled hydromorphone can be prepared using a modification of the procedure described in Journal of Medicinal Chemistry, 1977, vol 20, 164-165 and Tetrahedron Letters Vol. 25, 3335-3338, 1984. A solution of 2.99 g (10 mmol) of anhydrous D2-Hydrocodone **O-13** in 25 ml of CHCl_3 is to be added during 2 min to a well-stirred solution of 15 g (59.9 mmol) of BBr_3 in 175 ml of CHCl_3 maintained in the range 23-26 degrees C. A 10 ml portion of CHCl_3 , which is added to rinse the addition funnel, is added to the reaction mixture and stirring is continued for 15 min at 23-26 degrees C. The reaction mixture which will consist of a suspension of white solid (in CHCl_3) is then poured into a well-stirred mixture of 80 g of ice and 20 ml of concentrated (28-30% NH_3) NH_4OH . The two-phase system is kept at -5 to 0 degrees C for 0.5 h (continuous stirring) and filtered. The resulting crystalline material is washed thoroughly with small portions of cold CHCl_3 and H_2O and dried to give 2.67 g (88.1%) of slightly off-white **MO-13** monohydrate.

EXAMPLES 37-40: SYNTHESIS OF LABELED ZOLPIDEM AND ZOLPIDEM HEMITARTRATE

These examples describe the synthesis of labeled zolpidem and zolpidem hemitartrate. See Figure 15.

EXAMPLE 37: Synthesis of D6-Zolpidem, (**z02**)

D6-Zolpidem can be prepared using a modification of the procedure described in US Patent No. 6,281,360. Suspend 5 g of 2-(p-tolyl)-6-methylimidazo[1,2a]pyridine-3-acetic acid **z01** in 50 ml of dry dichloromethane and add 2.5 g of oxalylchloride. Then, add slowly under stirring 5 drops of dimethylformamide (gas formation occurs) and, after 3 hours, add 1.1 g of oxalylchloride. Stir the reaction mixture for 1 hour then bubble slowly gaseous $\text{NH}(\text{CD}_3)_2$ through the reaction mixture for 1.5 hours. After termination, wash the reaction mixture with 2x10 ml of water, dry the organic phase with sodium sulfate and evaporate the solvent under reduced pressure. After adding 25 ml of ethyl acetate to the rest, a solid precipitates. Filter off the precipitate, wash with 2x5 ml of ethyl acetate and dry in a vacuum oven at 40 degrees C. The yield should be 4.3 g of **z02**.

EXAMPLE 38: Synthesis of $^{15}\text{N},^{13}\text{C}$ -Zolpidem, (**z04**)

$^{15}\text{N},^{13}\text{C}$ -Zolpidem can be prepared using a modification of the procedure described in US Patent No. 6,281,360 and Tetrahedron 58 (2002) 8779-8791. Suspend 5 g of 2-(p-tolyl)-6-methylimidazo[1,2a]pyridine-3-acetic acid **z01** in 50 ml of dry dichloromethane and add 2.5 g of oxalylchloride. Then, add slowly under stirring 5 drops of dimethylformamide (gas formation occurs) and, after 3 hours, add 1.1 g of oxalylchloride. Stir the reaction mixture for 1 hour then bubble slowly gaseous $^{15}\text{NH}_2\text{CH}_3$ through the reaction mixture for 1.5 hours. After termination, wash the reaction mixture with 2x10 ml of water, dry the organic phase with sodium sulfate and

evaporate the solvent under reduced pressure. After adding 25 ml of ethyl acetate to the rest, a solid precipitates. Filter off the precipitate, wash with 2x5 ml of ethyl acetate and dry in a vacuum oven at 40 degrees C. The yield should be 4.3 g of **zo3**.

To a solution of **zo3** (1.63 mmol) in DMF will be added $^{13}\text{CH}_3\text{I}$ (2.4 mmol) and 55 wt% of NaH (2.0 mmol) at 0 degrees C. After stirring for 3 h, the reaction mixture is quenched with sat. NH_4Cl (2 ml). The resulting mixture will be diluted with ether and washed with water and brine, dried over MgSO_4 and filtered. The filtrate will be evaporated in vacuo to give 508 mg of a crude product, which will be purified by silica gel column chromatography.

EXAMPLES 39-40: Synthesis of D6-Zolpidem Hemitartrate and $^{15}\text{N},^{13}\text{C}$ -Zolpidem Hemitartrate
D6-Zolpidem hemitartrate and $^{15}\text{N},^{13}\text{C}$ -zolpidem hemitartrate can be prepared using a modification of the procedure described in US Patent No. 6,281,360. Dissolve 1 g of labeled zolpidem in 10 ml of methanol and add a solution of 0.244 g of L-tartaric acid in 5 ml of methanol. After cooling, white crystals are formed. Collect the solid by filtration, wash with cold methanol and dry.

EXAMPLE 41: SYNTHESIS OF DEUTERATED BUPRENORPHINE

This example describes the synthesis of deuterated buprenorphine. See **Figure 16**. Deuterated buprenorphine can be prepared using a modification of the procedure described in GB1136214 and US Patent No. 3,433,791. Dissolve 40 g of **bb1** in ethanol (300 ml) and deuterate it with D_2 gas in the presence of Raney nickel catalyst (10 g) at 161-164 celsius and 164-182 atmosphere for four hours. Concentrate the solution after removing the catalyst by filtration will afford a white crystalline solid (26 g). This material is recrystallized from ethanol.

EXAMPLE 42-46: SYNTHESIS OF LABELED TRAMADOL

These examples describe the synthesis of labeled tramadol. See **Figure 17**.

General Procedure:

Various labeled tramadols can be prepared using a modification of the procedure described in Tetrahedron Letters 41 (2000) 6635-6638 and J. Org. Chem. 39, (1974) 3875-3877.

Methylated hydroxylamine resin **t4**:

To 2 g hydroxylamine resin **t1** (0.5 mmol/gram loading) is added 2 mmol Boc anhydride and 2 mmol diisopropylethylamine in 10 ml THF and stirred for one hour. The resin is filtered and washed with dimethylformamide three times. To the resin is added 20 mmol NaH in dimethylformamide and the suspension is stirred for 16 h at room temperature. A quantity of 40 mmol of the labeled alkyl iodide R^1I is then added and stirred for another 16 h. The solution is

filtered from the resin and the resin is washed with dimethylformamide several times. The resin is then treated with 20% trifluoroacetic acid in dichloromethane for 30 min after which it is filtered and washed three times with dimethylformamide. This will yield 1 mmol **t4** on resin.

Labeled Tramadol t10:

To 2 g of methylated hydroxylamine resin **t4** (1 mmol) is added 2 mmol trimethylsilyl chloride and 2 mmol triethylamine in 10 ml tetrahydrofuran. This suspension is stirred for one hour at room temperature. A quantity of 2 mmol chloromethylethyl ether is added to the suspension and stirred for 30 min at room temperature. Finally 2 mmol of cyclohexanone trimethylsilyl enol ether is added to the suspension and stirred for another hour at room temperature. The resin is then filtered and washed three times with tetrahydrofuran. The resin bound ketone **t6** is then reacted with 3-methoxyphenyl magnesium bromide (10 mmol in 50 ml tetrahydrofuran) at room temperature for 16 h to give tertiary alcohol **t8**. The resin is then filtered and washed three times with THF and three times with dichloromethane. The resin is then treated with labeled $R^2OSO_2CF_3$ in dichloromethane (5 mmol $R^2OSO_2CF_3$ in 20 ml dichloromethane) for 16 h at room temperature. Finally the resin is treated with 5mmol triethylamine in 20 ml dichloromethane at room temperature for 16 h to cleave the labeled tramadol **t10** from the resin. The resin is filtered and the filtrate is dried under vacuum and purified by chromatography.

Labeled methyl-trifluorosulfonate:

Labeled methyl iodide (1 mmol) is added with stirring to 0.259 g (1 mmol) of silver triflate in 3 ml of carbon tetrachloride at ambient temperature. The solid silver iodide is filtered off and the labeled methyl triflate is isolated by removing the carbon tetrachloride in vacuo.

EXAMPLE 42: Synthesis of ^{13}C -Tramadol.

Follow the above procedures, use CH_3I for R^1I and $^{13}CH_3I$ for R^2I .

EXAMPLE 43: Synthesis of $^{13}C_2$ -Tramadol.

Follow the above procedures, use $^{13}CH_3I$ for R^1I and $^{13}CH_3I$ for R^2I .

EXAMPLE 44: Synthesis of D3-Tramadol

Follow the above procedures, use CH_3I for R^1I and CD_3I for R^2I .

EXAMPLE 45: Synthesis of $^{13}C,D_3$ -Tramadol

Follow the above procedures, use CH_3I for R^1I and $^{13}CD_3I$ for R^2I .

EXAMPLE 46: Synthesis of $^{13}C_2,D_3$ -Tramadol


Follow the above procedures, use $^{13}CH_3I$ for R^1I and $^{13}CD_3I$ for R^2I .

References Cited

Numerous references, including patents, patent applications and various publications, are cited and discussed in the description of this invention. The citation and/or discussion of such references is provided merely to clarify the description of the present invention and is not an admission that any such reference is "prior art" to the invention described herein. All references cited and discussed in this specification are incorporated herein by reference in their entirety and to the same extent as if each reference was individually incorporated by reference.

CLAIMS:

1. An isotopically labeled compound represented by general Formula I:



wherein,

at least two of the atoms of the structure are ^2H , ^{13}C , ^{15}N , ^{18}O , or a mixture thereof;

R_1 is selected from chlorine, fluorine and nitro;


R_2 is selected from hydrogen, fluorine, or chlorine;

R_3 is selected from hydrogen, deuterium, carboxy ($-\text{COOH}$) or hydroxy;

R_4 is selected from no substituent or oxygen;


X_1 is selected from oxo, ^{18}O , sulphur ($=\text{S}$) or aminomethyl ($-\text{NHCH}_3$);

X_2 is selected from no substituent, hydrogen, methyl, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_3)_2$, trifluoroethyl ($-\text{CH}_2\text{CF}_3$), or methylenecyclopropyl ($-\text{CH}_2-\text{CH}(\text{CH}_2)_2$); or



X_1 and X_2 together represent the bridge ; and


when X_2 is no substituent or X_1 is amino methyl ($-\text{NHCH}_3$), there is a double bond between nitrogen-1 and carbon-2 and a single bond between carbon-2 and X_2 ; and




when X_1 is oxo or ^{18}O , or X_1 and X_2 together represent the bridge , there is a single bond between nitrogen-1 and carbon-2 and a double bond between carbon-2 and X_2 ;

and pharmaceutically acceptable salts and solvates thereof.


2. The compound of claim 1, wherein the compound has the structure:




3. The compound of claim 1, wherein the compound has the structure:




4. The compound of claim 1, wherein the compound has the structure:



5. The compound of claim 1, wherein the compound has the structure:




6. The compound of claim 1, wherein the compound has the structure:



7. A method for producing the compounds of Formula I, wherein there is a C-N single bond between nitrogen 1 and carbon 2, X₁ is oxygen and there is a C=O double bond between X₁ and carbon 2, and X₂ is hydrogen and R₃ is hydrogen and R₄ is no substituent, comprising:

(a) condensing a compound of Formula **B1**:



B1


wherein

the compound B1 contains from zero to at least one isotopic label comprising ²H, ¹³C, ¹⁵N, ¹⁸O, or a mixture thereof;

R1 is selected from chlorine, fluorine or nitro; and

R2 is selected from hydrogen, fluorine, or chlorine,

with an isotopically labeled compound **B2**:



B2


wherein

at least one atom labeled with “*” is an isotopic label selected from the group consisting of ¹³C, ¹⁵N, ¹⁸O, ²H, and a mixture thereof;

Y is a leaving group;

P1 is an amine protecting group;


(b) then removing the protecting group P1 to produce a compound of formula **B3**:



wherein


compound **B3** contains at least two isotopic labels; and

- (c) then intramolecularly dehydrating **B3** to form a compound of formula **B4**;




wherein

compound **B4** contains at least two isotopic labels.

8. A method for producing compounds of Formula I, wherein there is a C-N single bond between nitrogen 1 and carbon 2, X₁ is oxygen and there is a C=O double bond between X₁ and carbon 2, and R₃ is hydrogen, R₄ is no substituent, and X₂ is methyl (-CH₃), -CH₂CH₂N(CH₂CH₃)₂, trifluoroethyl (-CH₂CF₃), or methylenecyclopropyl (, comprising:

- (a) treating an isotopically labeled compound **B4** with a strong base; and
- (b) then treating the compound with an alkyl halide to produce a compound of formula **B5**:




wherein

compound **B5** contains at least two isotopic labels.

9. A method for producing compounds of Formula I, wherein there is a C-N single bond between nitrogen 1 and carbon 2, X₂ is hydrogen or methyl, X₁ is oxygen and there is a C-O double bond between X₁ and carbon 2, and R₃ is hydroxy, and R₄ is no substituent, comprising:

(a) reacting a compound of Formula **B5**:




B5

wherein

compound **B5** contains at least two isotopic labels,

with an electron poor peroxyacid;

(b) then treating the resulting product with a compound of formula **B6**;



B6

wherein


R₁ and R₂ are independently selected from C₁-C₆ alkyl; and

(c) then saponifying the ester intermediate


10. A method for producing compounds of Formula I, wherein there is a C-N single bond

between nitrogen 1 and carbon 2, X₁ and X₂ together represent the bridge hydrogen and R₄ is no substituent, comprising:

(a) treating a compound of Formula **B7**:



, and R₃ is

**B7**


wherein

compound **B7** contains at least two isotopic labels,


with a base;

(b) then reacting the compound with diethylchlorophosphate; and

(c) then reacting the compound with a compound of formula **B8**

**B8**

11. An isotopically labeled compound represented by Formula **II**:

**II**


wherein

at least two of the atoms of the structure are present as isotopes ^2H , ^{13}C , or ^{15}N ;

R_1 is selected from hydrogen or methyl,


and pharmaceutically acceptable salts, solvates, and mixtures thereof.

12. The compound of claim 11 wherein the compound is from:



13. A method for producing the compounds of Formula II, wherein R_5 has the meaning of hydrogen or methyl, comprising:

reducing a compound of Formula A1



A1


wherein

compound A1 contains at least two isotopic labels; and

X_3 is hydroxy or oxo.

14. A method for producing compounds of Formula II, wherein R_5 has the meaning of hydrogen, comprising

reducing a compound of Formula A2:



A2


wherein

compound A2 contains at least two isotopic labels; and

the nitroalkene can be present in the E or Z form or a mixture thereof.

15. A method for producing compounds of Formula II, wherein R_5 has the meaning of hydrogen or methyl, comprising:

reducing a compound of Formula A3




A3

wherein

compound A3 contains no or at least two isotopic labels; and

in the presence of a NHR_6 , wherein R_6 is selected from hydrogen or methyl.

16. A method for producing compounds of Formula I, wherein R₅ has the meaning of methyl, reducing a compound of formula XV




A4.

wherein

compound A4 contains no or at least two isotopic labels.

17. An isotopically labeled compound of Formula III:



III

wherein

at least two of the atoms in the structure are ²H, ¹³C, ¹⁵N, ¹⁸O, or a mixture thereof.

18. A method for preventing or stopping drug abuse, which comprises:
- (a) prescribing a labeled drug to a patient;
 - (b) recording the labeled drug prescription in a registry accessible to providers;
 - (c) testing a fluid or tissue sample from the patient for the presence of labeled drug and unlabeled drug; and
 - (d) refusing to prescribe the drug to a patient testing positive for unlabeled drug or a labeled drug not recorded in the registry.
19. A method for preventing or stopping drug abuse, which comprises:
- (a) accessing a patient's prescription in a registry;
 - (b) testing a fluid or tissue sample from the patient for the presence of labeled and unlabeled drug if the patient has a current prescription for a labeled drug recorded in the registry; and
 - (c) refusing to prescribe the drug to a patient who tests positive for the presence of unlabeled drug and has a current prescription for a labeled drug recorded in the registry.

20. A method for monitoring patient compliance with a prescription for a controlled pharmaceutical agent, which method comprises:

- (a) prescribing a controlled pharmaceutical agent that has been labeled to a patient;
- (b) recording the labeled controlled pharmaceutical agent prescription in a registry;
- (c) testing a fluid or tissue sample from the patient for the presence of labeled and unlabeled controlled pharmaceutical agent; and
- (d) identifying a patient who tests negative for the presence of labeled controlled pharmaceutical agent;

wherein the patient who tests negative for the presence of labeled controlled pharmaceutical agent is a non-compliant patient.

21. A method for monitoring patient compliance with a prescription for a DEA schedule II to V drug, which method comprises:

- (a) accessing a patient's prescription information record in a registry;
- (b) testing a fluid or tissue sample from the patient for the presence of labeled and unlabeled drug; and
- (c) identifying a patient with a current prescription for a labeled drug recorded in the registry and who tests negative for the presence of labeled drug;

wherein the patient with a current prescription for a labeled drug recorded in the registry who tests negative for the presence of labeled drug is a non-compliant patient.

22. A method for facilitating replacement drug prescription by a provider, which method comprises:

- (a) accessing a registry;
- (b) prescribing a replacement drug prescription to a patient with a current labeled drug prescription recorded on the registry;

wherein the labeled drug prescribed and recorded in the registry is not immediately available to the patient.

23. A method for safely tapering a drug, which method comprises:

- (a) prescribing a taper labeled drug regimen to a patient;
- (b) recording the taper labeled drug regimen in a registry;
- (c) testing the patient's tissue or body fluid for unlabeled drug and labeled drug;

(d) identifying a patient who is properly adhering to the taper labeled drug regimen when the patient tests positive for a labeled drug appropriate to the taper regimen at the time of testing; or

(e) identifying a patient who is not properly adhering to the taper labeled drug regimen when the patient tests positive for an unlabeled drug or a labeled drug that is not appropriate to the taper regimen at the time of testing or who tests negative for unlabeled drug and labeled drug.

24. The method of any one of claims 18 to 21 or 23, wherein the testing step comprises testing the fluid or tissue sample for the presence of labeled drug using gas or liquid chromatography and mass spectrometry.

25. The method of any one of claims 18 to 22, wherein the labeled drug is a benzodiazepine.


26. The method of any one of claims 18 to 22, wherein the labeled drug is an amphetamine.

27. The method of any one of claims 18 to 22, wherein the labeled drug is methylphenidate.

28. The method of any one of claims 18 to 22, wherein the labeled drug is an opioid.

29. A pharmaceutical composition comprising an isotopically labeled compound of any one of claims 1 to 6, 11, 12, or 17 and a pharmaceutically acceptable carrier.

30. An isotopically labeled compound represented by general Formula IV:



wherein

at least one of the atoms of the structure is ^2H , ^{13}C , ^{15}N , ^{18}O , or a mixture thereof;

R_1 is selected from hydrogen, deuterium, $-\text{OH}$, or ^{18}OH ;

R_2 is selected from hydrogen or deuterium;

R₃ is selected from hydrogen or deuterium; or
R₂ and R₃ are not present and there is a C-C double bond between carbon 2 and carbon 3;
R₄ is selected from hydrogen or deuterium;
R₅ is selected from -OH or ¹⁸OH;
R₆ is selected from -H, -CH₃ or -¹³CH₃; or
R₄ and R₅ together form oxo (=O or =¹⁸O); and
pharmaceutically acceptable salts, solvates, and mixtures thereof

31. An isotopically labeled methadone, wherein the labeled methadone comprises at least two isotopic labels selected from ²H, ¹³C, ¹⁵N, ¹⁸O, and a mixture thereof; and pharmaceutically acceptable salts, solvates, and mixtures thereof.

32. A pharmaceutical composition comprising a mixture of a drug having different labels in a specified ratio and a pharmaceutically acceptable carrier.

33. The method according to any one of claims 18 to 23, wherein the labeled drug comprises a mixture of drugs having different labels in a specified ratio.

34. A method for prescribing a labeled controlled drug to a patient, which comprises
(a) creating a drug registry containing information on prescriptions written for controlled drugs and the identity of the patient receiving such prescriptions,
(b) recording all controlled drug prescriptions in the registry,
(c) interrogating the drug registry for information on the patient, and
(d) prescribing a labeled controlled drug to a patient only if the patient does not have an unexpired prescription for the same controlled drug recorded in the registry.


35. The method of claim 34, further comprising testing tissue or body fluid of the patient for the presence of labeled and unlabeled versions of the controlled substance before the prescribing step.

36. The method of claim 35, further comprising recording the test results in the registry.

37. A method for prescribing a labeled controlled drug to a patient, which comprises

- (a) creating a drug registry containing information on prescriptions written for controlled drugs and the identity of the patient receiving such prescriptions;
- (b) recording all controlled drug prescriptions and patient identities in the registry,
- (c) interrogating the drug registry for information on the patient,
- (d) testing the patient's tissue or body fluid for the presence of labeled or unlabeled controlled drug, and
- (e) prescribing a labeled controlled drug to a patient only if the patient does not have:
 - (i) a positive test result for an unlabeled controlled drug or a labeled controlled drug that is not recorded on the registry, or
 - (ii) an unexpired prescription for the same controlled drug recorded in the registry.

38. An isotopically labeled fentanyl having the structural formula:




wherein

the labeled fentanyl comprises at least two isotopic labels independently selected from ^2H , ^{13}C , ^{15}N , and ^{18}O ; and pharmaceutically acceptable salts and solvates thereof.

39. A method for prescribing a labeled controlled drug to a patient, which comprises
- (a) creating a drug registry containing information on prescriptions written for controlled drugs and the identity of the patient receiving such prescriptions,
 - (b) recording all controlled drug prescriptions in the registry,
 - (c) interrogating the drug registry for information on the patient,
 - (d) comparing a prescription for a labeled controlled drug with the registry information on the patient; and
 - (e) issuing the prescription only if the patient does not have an unexpired prescription for the same controlled drug recorded in the registry.


40. An isotopically labeled tramadol having the structural formula:



wherein

the labeled tramadol comprises at least one isotopic label independently selected from ^2H , ^{13}C , ^{15}N , and a mixture thereof; and pharmaceutically acceptable salts, solvates, and mixtures thereof.


41. An isotopically labeled zolpidem having the structural formula:



wherein

the labeled zolpidem comprises at least one isotopic label independently selected from ^2H , ^{13}C , ^{15}N , and mixtures thereof; and pharmaceutically acceptable salts, solvates, and mixtures thereof.

42. An isotopically labeled buprenorphine having the structural formula:



wherein the labeled buprenorphine comprises at least one isotopic label independently selected from ^2H , ^{13}C , and ^{15}N ; and pharmaceutically acceptable salts, solvates, and mixtures thereof.

43. The isotopically labeled compound of claim 30, wherein at least one of the atoms of the structure is ^2H , ^{18}O , or a mixture thereof;
- R_1 is selected from hydrogen or deuterium;
- R_2 and R_3 are not present and there is a C-C double bond between carbon 2 and carbon 3;
- R_4 is selected from hydrogen or deuterium;
- R_5 is selected from $-\text{OH}$ or ^{18}OH ;
- R_6 is H; and
- pharmaceutically acceptable salts, solvates, and mixtures thereof.
44. The isotopically labeled compound of claim 30, wherein at least one of the atoms of the structure is ^2H or ^{18}O ;
- R_1 is selected from hydrogen or deuterium;
- R_2 is selected from hydrogen or deuterium;
- R_3 is selected from hydrogen or deuterium;
- R_4 and R_5 together form oxo ($=\text{O}$ or $=^{18}\text{O}$);
- R_6 is H; and
- pharmaceutically acceptable salts, solvates, and mixtures thereof.
45. A pharmaceutical composition comprising an isotopically labeled compound of any one of claims 40-44 and a pharmaceutically acceptable carrier.
46. The method of any one of claims 18 to 22, wherein the labeled drug is selected from the group consisting of buprenorphine, zolpidem, and tramadol.
47. The method of claim 28, wherein the opioid is morphine or hydromorphone.
48. The compound of claim 30, wherein 2 or more atoms of the structure are ^2H , ^{13}C , ^{15}N , ^{18}O , or a mixture thereof.
49. The isotopically labeled tramadol of claim 40 comprising 2 or more isotopic labels selected from ^2H , ^{13}C , ^{15}N , and mixtures thereof.

50. The isotopically labeled zolpidem of claim 41 comprising 2 or more isotopic labels from ^2H , ^{13}C , ^{15}N , and mixtures thereof.
51. The isotopically labeled buprenorphine of claim 42 comprising 2 or more isotopic labels from ^2H , ^{13}C , ^{15}N , and mixtures thereof.
52. The isotopically labeled compound of claim 30, wherein 2 or more atoms of the structure are ^2H , ^{13}C , ^{15}N , ^{18}O , and mixtures thereof.
53. A method for identifying a non-compliant patient who does not comply with a prescription for medication, comprising:
- (a) prescribing a medication to a patient for a period of time comprising a first predetermined interval and a second predetermined interval wherein the first predetermined interval and second predetermined interval are consecutive;
 - (b) providing the patient with a supply of the medication adequate to cover the period to time, wherein the supply comprises units of the medication having a plurality of different labels;
 - (c) instructing the patient to self-administer the labeled units having a first label during the first predetermined time;
 - (d) instructing the patient to self-administer the labeled units having a second label during the second predetermined time, the second label being different from the first label;
 - (e) testing the patient for the presence of the first label during the second predetermined interval;
 - (f) testing the patient for the presence of the second label during the second predetermined interval; and
 - (g) identifying a patient testing negative for the presence of the first label and the second label as non-compliant with the prescription medication for the period of time.
54. The method of claim 53, wherein the period of time is about one month.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




FIGURE 6




FIGURE 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12

**Figure 13**




Figure 14




Figure 15




Figure 16




Figure 17